US5849719A
(en)
|
1993-08-26 |
1998-12-15 |
The Regents Of The University Of California |
Method for treating allergic lung disease
|
US6727230B1
(en)
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6429199B1
(en)
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
CA2560114A1
(en)
*
|
1994-07-15 |
1996-02-01 |
The University Of Iowa Research Foundation |
Immunomodulatory oligonucleotides
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US6239116B1
(en)
*
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US7935675B1
(en)
*
|
1994-07-15 |
2011-05-03 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US7422902B1
(en)
*
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
ES2283012T3
(es)
|
1996-01-04 |
2007-10-16 |
Novartis Vaccines And Diagnostics, Inc. |
Bacterioferritina de helicobacter pylori.
|
WO1997028259A1
(en)
*
|
1996-01-30 |
1997-08-07 |
The Regents Of The University Of California |
Gene expression vectors which generate an antigen specific immune response and methods of using the same
|
FR2750704B1
(fr)
|
1996-07-04 |
1998-09-25 |
Rhone Poulenc Rorer Sa |
Procede de production d'adn therapeutique
|
US5856462A
(en)
*
|
1996-09-10 |
1999-01-05 |
Hybridon Incorporated |
Oligonucleotides having modified CpG dinucleosides
|
AU768178B2
(en)
*
|
1996-10-11 |
2003-12-04 |
Regents Of The University Of California, The |
Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
|
ES2241042T3
(es)
*
|
1996-10-11 |
2005-10-16 |
The Regents Of The University Of California |
Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
WO1998037919A1
(en)
*
|
1997-02-28 |
1998-09-03 |
University Of Iowa Research Foundation |
USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
|
US6406705B1
(en)
*
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
DE69841122D1
(de)
*
|
1997-03-10 |
2009-10-15 |
Coley Pharm Gmbh |
Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
|
US6426334B1
(en)
|
1997-04-30 |
2002-07-30 |
Hybridon, Inc. |
Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
|
WO1998051278A2
(en)
|
1997-05-14 |
1998-11-19 |
Inex Pharmaceuticals Corporation |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
US20030104044A1
(en)
*
|
1997-05-14 |
2003-06-05 |
Semple Sean C. |
Compositions for stimulating cytokine secretion and inducing an immune response
|
EP0983289A4
(en)
*
|
1997-05-19 |
2001-04-25 |
Merck & Co Inc |
OLIGONUCLEOTIDE ADJUVANT
|
CA2301575C
(en)
|
1997-05-20 |
2003-12-23 |
Ottawa Civic Hospital Loeb Research Institute |
Vectors and methods for immunization or therapeutic protocols
|
EP2085090A3
(en)
|
1997-06-06 |
2012-05-02 |
The Regents of the University of California |
Inhibitors of DNA immunostimulatory sequence activity
|
US6589940B1
(en)
|
1997-06-06 |
2003-07-08 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
EP1374894A3
(en)
*
|
1997-06-06 |
2004-09-22 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
US20040006034A1
(en)
*
|
1998-06-05 |
2004-01-08 |
Eyal Raz |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
ATE353657T1
(de)
*
|
1997-09-05 |
2007-03-15 |
Univ California |
Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
|
GB9724531D0
(en)
|
1997-11-19 |
1998-01-21 |
Smithkline Biolog |
Novel compounds
|
BR9907691B1
(pt)
|
1998-02-05 |
2011-05-31 |
|
derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6218371B1
(en)
*
|
1998-04-03 |
2001-04-17 |
University Of Iowa Research Foundation |
Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
|
HUP0101619A3
(en)
*
|
1998-04-09 |
2003-11-28 |
Smithkline Beecham Biolog |
Adjuvant compositions
|
GB9808866D0
(en)
|
1998-04-24 |
1998-06-24 |
Smithkline Beecham Biolog |
Novel compounds
|
JP2002513763A
(ja)
*
|
1998-05-06 |
2002-05-14 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
Cpgオリゴヌクレオチドを使用して寄生生物感染および関連する疾患を予防および処置するための方法
|
IL139646A0
(en)
*
|
1998-05-14 |
2002-02-10 |
Coley Pharm Group Inc |
Methods for regulating hematopoiesis using cpg-oligonucleotides
|
NZ528940A
(en)
|
1998-05-19 |
2005-02-25 |
Res Dev Foundation |
Method to continually harvest an Acacia victoriae plant tissue and a hairy root tissue culture infected with Agrobacterium rhizogenes
|
IL139813A0
(en)
*
|
1998-05-22 |
2002-02-10 |
Loeb Health Res Inst At The Ot |
Methods and products for inducing mucosal immunity
|
US6881561B1
(en)
|
1998-05-27 |
2005-04-19 |
Cheil Jedang Corporation |
Endonuclease of immune cell, process for producing the same and immune adjuvant using the same
|
KR19990086271A
(ko)
*
|
1998-05-27 |
1999-12-15 |
손경식 |
면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
|
US6562798B1
(en)
*
|
1998-06-05 |
2003-05-13 |
Dynavax Technologies Corp. |
Immunostimulatory oligonucleotides with modified bases and methods of use thereof
|
US6693086B1
(en)
*
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
JP2002521489A
(ja)
*
|
1998-07-27 |
2002-07-16 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
CpGオリゴヌクレオチドの立体異性体および関連する方法
|
JP4422903B2
(ja)
|
1998-07-31 |
2010-03-03 |
株式会社癌免疫研究所 |
癌抑制遺伝子wt1の産物に基づく癌抗原
|
EP2272859B1
(en)
|
1998-08-07 |
2014-10-22 |
University of Washington |
Immunological herpes simplex virus antigens and methods for use thereof
|
PT1104306E
(pt)
*
|
1998-08-10 |
2006-05-31 |
Antigenics Inc |
Composicoes de cpg e adjuvantes de saponina e seus metodos
|
ES2394458T3
(es)
*
|
1998-09-09 |
2013-01-31 |
Genzyme Corporation |
Metilación de vectores plasmídicos
|
US6692752B1
(en)
|
1999-09-08 |
2004-02-17 |
Smithkline Beecham Biologicals S.A. |
Methods of treating human females susceptible to HSV infection
|
FR2783170B1
(fr)
*
|
1998-09-11 |
2004-07-16 |
Pasteur Merieux Serums Vacc |
Emulsion immunostimulante
|
AU766492B2
(en)
*
|
1998-09-18 |
2003-10-16 |
Dynavax Technologies Corporation |
Methods of treating IgE-associated disorders and compositions for use therein
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
AU776288B2
(en)
*
|
1998-10-05 |
2004-09-02 |
Regents Of The University Of California, The |
Methods and adjuvants for stimulating mucosal immunity
|
KR100629028B1
(ko)
|
1998-10-16 |
2006-09-26 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
애쥬번트 시스템 및 백신
|
KR100829407B1
(ko)
|
1998-12-08 |
2008-05-15 |
코릭사 코포레이션 |
클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
|
EP2374889A3
(en)
|
1998-12-08 |
2012-02-22 |
GlaxoSmithKline Biologicals SA |
Novel compounds
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
US7198920B1
(en)
*
|
1999-01-29 |
2007-04-03 |
Corika Corporation |
HER-2/neu fusion proteins
|
JP2002536344A
(ja)
*
|
1999-02-05 |
2002-10-29 |
ジエンザイム コーポレイション |
抗腫瘍免疫を発生させるためのカチオン性脂質の使用
|
EP2204186B1
(en)
|
1999-02-17 |
2016-04-06 |
CSL Limited |
Immunogenic complexes and methods relating thereto
|
EP1154790B1
(en)
|
1999-02-26 |
2004-10-20 |
Chiron S.r.l. |
Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
|
CA2689696C
(en)
|
1999-02-26 |
2013-08-06 |
Novartis Vaccines And Diagnostics, Inc. |
Microemulsions with adsorbed macromolecules and microparticles
|
ATE451461T1
(de)
|
1999-03-12 |
2009-12-15 |
Glaxosmithkline Biolog Sa |
Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
|
GB9909077D0
(en)
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Biolog |
Novel compositions
|
FR2790955B1
(fr)
*
|
1999-03-19 |
2003-01-17 |
Assist Publ Hopitaux De Paris |
Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
|
JP2000262247A
(ja)
*
|
1999-03-19 |
2000-09-26 |
Asama Kasei Kk |
免疫調節剤、免疫調節食品および免疫調節飼料
|
AR022963A1
(es)
|
1999-03-19 |
2002-09-04 |
Smithkline Beecham Biolog |
Vacuna
|
IL145731A0
(en)
|
1999-04-02 |
2002-07-25 |
Corixa Corp |
A polypetide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same
|
AU4343700A
(en)
|
1999-04-12 |
2000-11-14 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Oligodeoxynucleotide and its use to induce an immune response
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
WO2000062800A2
(en)
|
1999-04-19 |
2000-10-26 |
Smithkline Beecham Biologicals Sa |
Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
WO2000067023A1
(en)
*
|
1999-04-29 |
2000-11-09 |
Coley Pharmaceutical Gmbh |
Screening for immunostimulatory dna functional modifyers
|
ES2250151T3
(es)
*
|
1999-06-29 |
2006-04-16 |
Glaxosmithkline Biologicals S.A. |
Uso de cpg como adyuvante de vacuna contra vih.
|
GB9915204D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Smithkline Beecham Biolog |
Vaccine
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
FR2795963A1
(fr)
*
|
1999-07-08 |
2001-01-12 |
Pasteur Merieux Serums Vacc |
Polynucleotide immunostimulant
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
GB9918319D0
(en)
|
1999-08-03 |
1999-10-06 |
Smithkline Beecham Biolog |
Vaccine composition
|
US20050226890A1
(en)
*
|
1999-08-12 |
2005-10-13 |
Cohen David I |
Tat-based vaccine compositions and methods of making and using same
|
WO2001012223A2
(en)
|
1999-08-19 |
2001-02-22 |
Dynavax Technologies Corporation |
Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
|
WO2001015726A2
(en)
*
|
1999-08-27 |
2001-03-08 |
Inex Pharmaceuticals Corp. |
Compositions for stimulating cytokine secretion and inducing an immune response
|
NZ517929A
(en)
*
|
1999-09-25 |
2004-02-27 |
Univ Iowa Res Found |
Immunostimulatory nucleic acids
|
US6949520B1
(en)
*
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
CA2721011A1
(en)
|
1999-10-22 |
2001-05-03 |
Aventis Pasteur Limited |
Modified gp100 and uses thereof
|
US7223398B1
(en)
|
1999-11-15 |
2007-05-29 |
Dynavax Technologies Corporation |
Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
|
WO2001045750A1
(en)
*
|
1999-12-21 |
2001-06-28 |
The Regents Of The University Of California |
Method for preventing an anaphylactic reaction
|
WO2001051500A1
(en)
*
|
2000-01-14 |
2001-07-19 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
AT409085B
(de)
*
|
2000-01-28 |
2002-05-27 |
Cistem Biotechnologies Gmbh |
Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
|
WO2001055341A2
(en)
*
|
2000-01-31 |
2001-08-02 |
The Regents Of The University Of California |
Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
|
US7585847B2
(en)
*
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
FR2805264B1
(fr)
*
|
2000-02-18 |
2002-04-12 |
Aventis Pasteur |
Oligonucleotides immunostimulants
|
FR2805265B1
(fr)
*
|
2000-02-18 |
2002-04-12 |
Aventis Pasteur |
Oligonucleotides immunostimulants
|
DE60143425D1
(de)
*
|
2000-02-23 |
2010-12-23 |
Smithkline Beecham Biolog |
Neue verbindungen
|
US20030130217A1
(en)
*
|
2000-02-23 |
2003-07-10 |
Eyal Raz |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
AU4175101A
(en)
*
|
2000-02-23 |
2001-09-03 |
Univ California |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US20040131628A1
(en)
*
|
2000-03-08 |
2004-07-08 |
Bratzler Robert L. |
Nucleic acids for the treatment of disorders associated with microorganisms
|
US20030129251A1
(en)
|
2000-03-10 |
2003-07-10 |
Gary Van Nest |
Biodegradable immunomodulatory formulations and methods for use thereof
|
US7129222B2
(en)
|
2000-03-10 |
2006-10-31 |
Dynavax Technologies Corporation |
Immunomodulatory formulations and methods for use thereof
|
US7157437B2
(en)
|
2000-03-10 |
2007-01-02 |
Dynavax Technologies Corporation |
Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
|
US20010046967A1
(en)
|
2000-03-10 |
2001-11-29 |
Gary Van Nest |
Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
|
US20020098199A1
(en)
|
2000-03-10 |
2002-07-25 |
Gary Van Nest |
Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
|
WO2001076642A1
(en)
*
|
2000-04-07 |
2001-10-18 |
The Regents Of The University Of California |
Synergistic improvements to polynucleotide vaccines
|
EP2192128A3
(en)
|
2000-04-21 |
2010-09-22 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
CA2408328C
(en)
|
2000-05-10 |
2012-04-17 |
Aventis Pasteur Limited |
Immunogenic polypeptides encoded by mage minigenes and uses thereof
|
KR100829674B1
(ko)
|
2000-05-19 |
2008-05-16 |
코릭사 코포레이션 |
단당류 또는 이당류계 화합물을 이용한 전염성 및 다른질병의 예방 및 치료 방법
|
JP5139618B2
(ja)
|
2000-06-20 |
2013-02-06 |
コリクサ コーポレイション |
Mycobacteriumtuberculosisの融合タンパク質
|
JP2003535907A
(ja)
|
2000-06-22 |
2003-12-02 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
抗体誘導性細胞溶解を促進し、そして癌を処置するための方法
|
JP2004513615A
(ja)
|
2000-06-28 |
2004-05-13 |
コリクサ コーポレイション |
肺癌の治療および診断のための組成物および方法
|
HU227893B1
(en)
|
2000-06-29 |
2012-05-29 |
Glaxosmithkline Biolog Sa |
Vaccine compositions
|
GB0108364D0
(en)
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
KR100917101B1
(ko)
*
|
2000-08-04 |
2009-09-15 |
도요 보세키 가부시키가이샤 |
플렉시블 금속적층체 및 그 제조방법
|
AU2001285421A1
(en)
*
|
2000-08-10 |
2002-02-18 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Vaccine against rsv
|
WO2005090392A1
(en)
*
|
2004-03-16 |
2005-09-29 |
Inist Inc. |
Tat-based tolerogen compositions and methods of making and using same
|
UA79735C2
(uk)
|
2000-08-10 |
2007-07-25 |
Глаксосмітклайн Байолоджікалз С.А. |
Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
|
WO2002016549A2
(en)
*
|
2000-08-25 |
2002-02-28 |
Yeda Research And Development Co. Ltd. |
METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE
|
CA2419894A1
(en)
*
|
2000-09-15 |
2002-03-21 |
Coley Pharmaceutical Gmbh |
Process for high throughput screening of cpg-based immuno-agonist/antagonist
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
US20050019340A1
(en)
|
2000-10-18 |
2005-01-27 |
Nathalie Garcon |
Vaccines
|
EP2277895B1
(en)
|
2000-10-27 |
2013-08-14 |
Novartis Vaccines and Diagnostics S.r.l. |
Nucleic acids and proteins from streptococcus groups A & B
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
US20060142202A1
(en)
*
|
2000-12-08 |
2006-06-29 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
ES2307568T3
(es)
*
|
2000-12-08 |
2008-12-01 |
Coley Pharmaceutical Gmbh |
Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
|
CA2430691A1
(en)
*
|
2000-12-27 |
2002-07-04 |
Dynavax Technologies Corporation |
Immunomodulatory polynucleotides and methods of using the same
|
CN1496266A
(zh)
*
|
2001-01-12 |
2004-05-12 |
������ҩ��ʽ���� |
抗变态反应剂
|
EP1358884A1
(en)
*
|
2001-01-12 |
2003-11-05 |
Amato Pharmaceutical Products, Ltd. |
Preventives for microbial infections
|
US7128911B2
(en)
|
2001-01-19 |
2006-10-31 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of bone disease
|
EP1362594A1
(en)
*
|
2001-01-24 |
2003-11-19 |
Amato Pharmaceutical Products, Ltd. |
Anti-stress agents
|
DE10105234A1
(de)
|
2001-02-02 |
2002-08-29 |
Schoeller Textil Ag Sevelen |
Textile Fläche
|
GB0103171D0
(en)
|
2001-02-08 |
2001-03-28 |
Smithkline Beecham Biolog |
Vaccine composition
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
WO2002079253A1
(fr)
|
2001-03-22 |
2002-10-10 |
Haruo Sugiyama |
Peptide modifie wt1
|
US20030050268A1
(en)
*
|
2001-03-29 |
2003-03-13 |
Krieg Arthur M. |
Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
|
JP2005504513A
(ja)
|
2001-05-09 |
2005-02-17 |
コリクサ コーポレイション |
前立腺癌の治療及び診断のための組成物及び方法
|
CA2447793A1
(en)
|
2001-05-21 |
2002-11-28 |
Intercell Ag |
Immunostimulatory oligodeoxynucleic molecules
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
PT1404873E
(pt)
|
2001-06-21 |
2013-07-30 |
Dynavax Tech Corp |
Compostos de imunomodulação quiméricos e métodos de utilização dos mesmos
|
CN1636015A
(zh)
*
|
2001-06-29 |
2005-07-06 |
希龙公司 |
Hcv e1e2疫苗组合物
|
AU2002354644C1
(en)
|
2001-07-10 |
2009-04-30 |
Corixa Corporation |
Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
US7666674B2
(en)
|
2001-07-27 |
2010-02-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
|
AU2002318944A1
(en)
*
|
2001-08-01 |
2003-02-17 |
Coley Pharmaceutical Gmbh |
Methods and compositions relating to plasmacytoid dendritic cells
|
CA2456193A1
(en)
*
|
2001-08-03 |
2003-03-27 |
Medarex, Inc. |
Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
|
JP4607452B2
(ja)
*
|
2001-08-07 |
2011-01-05 |
ダイナバックス テクノロジーズ コーポレイション |
免疫調節性組成物、製剤およびその使用方法
|
US7354909B2
(en)
*
|
2001-08-14 |
2008-04-08 |
The United States Of America As Represented By Secretary Of The Department Of Health And Human Services |
Method for rapid generation of mature dendritic cells
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
WO2003015711A2
(en)
|
2001-08-17 |
2003-02-27 |
Coley Pharmaceutical Group, Inc. |
Combination motif immune stimulatory oligonucleotides with improved activity
|
EP2518142B1
(en)
|
2001-08-24 |
2015-07-15 |
UVic Industry Partnerships Inc. |
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
|
CA2458876A1
(en)
*
|
2001-08-30 |
2003-03-13 |
3M Innovative Properties Company |
Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
|
EP1435987A4
(en)
*
|
2001-09-07 |
2005-11-23 |
Univ Boston |
METHOD AND COMPOSITION FOR TREATING DISORDERS RELATED TO IMMUNE COMPLEXES
|
AU2002347404A1
(en)
*
|
2001-09-14 |
2003-04-01 |
Cytos Biotechnology Ag |
In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
|
EP1450856B1
(en)
*
|
2001-09-14 |
2009-11-11 |
Cytos Biotechnology AG |
Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
|
US20070015721A1
(en)
|
2001-09-20 |
2007-01-18 |
Andrew Beaton |
Hiv-gag codon-optimised dna vaccines
|
US7514415B2
(en)
|
2002-08-01 |
2009-04-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
|
WO2003027313A2
(en)
|
2001-09-24 |
2003-04-03 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
|
US20030119774A1
(en)
*
|
2001-09-25 |
2003-06-26 |
Marianna Foldvari |
Compositions and methods for stimulating an immune response
|
JP5230891B2
(ja)
*
|
2001-09-28 |
2013-07-10 |
株式会社癌免疫研究所 |
抗原特異的t細胞の新規な誘導方法
|
WO2003028758A1
(fr)
*
|
2001-09-28 |
2003-04-10 |
Haruo Sugiyama |
Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
CN1633598A
(zh)
*
|
2001-10-05 |
2005-06-29 |
科勒制药股份公司 |
Toll样受体3信号传导的激动剂和拮抗剂
|
US20030139364A1
(en)
*
|
2001-10-12 |
2003-07-24 |
University Of Iowa Research Foundation |
Methods and products for enhancing immune responses using imidazoquinoline compounds
|
TW200303759A
(en)
*
|
2001-11-27 |
2003-09-16 |
Schering Corp |
Methods for treating cancer
|
WO2004080430A2
(en)
*
|
2003-03-13 |
2004-09-23 |
3M Innovative Properties Company |
Methods of improving skin quality
|
EP1450821A1
(en)
*
|
2001-12-07 |
2004-09-01 |
Intercell AG |
Immunostimulatory oligodeoxynucleotides
|
WO2003050241A2
(en)
|
2001-12-12 |
2003-06-19 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services |
Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
|
ES2405790T3
(es)
|
2001-12-17 |
2013-06-03 |
Corixa Corporation |
Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
|
WO2003054161A2
(en)
|
2001-12-20 |
2003-07-03 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
US8466116B2
(en)
|
2001-12-20 |
2013-06-18 |
The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of CpG oligodeoxynucleotides to induce epithelial cell growth
|
CA2471092A1
(en)
*
|
2001-12-21 |
2003-07-10 |
Antigenics Inc. |
Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
|
US20040034223A1
(en)
*
|
2002-02-07 |
2004-02-19 |
Covalent Partners, Llc. |
Amphiphilic molecular modules and constructs based thereon
|
MXPA04007679A
(es)
*
|
2002-02-07 |
2005-12-05 |
Covalent Partners Llc |
Composiciones de nanopelicula y membrana.
|
US8088388B2
(en)
*
|
2002-02-14 |
2012-01-03 |
United Biomedical, Inc. |
Stabilized synthetic immunogen delivery system
|
CA2476626A1
(en)
|
2002-02-20 |
2003-08-28 |
Chiron Corporation |
Microparticles with adsorbed polypeptide-containing molecules
|
US7351413B2
(en)
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
US20070037769A1
(en)
*
|
2003-03-14 |
2007-02-15 |
Multicell Immunotherapeutics, Inc. |
Compositions and methods to treat and control tumors by loading antigen presenting cells
|
EP2258712A3
(en)
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
|
EP1485403A4
(en)
*
|
2002-03-15 |
2007-08-08 |
Multicell Immunotherapeutics I |
COMPOSITIONS AND METHOD FOR INTRODUCTION OR REINFORCEMENT OF ANTIBODY AND MAIN THISTOCOMPATIBILITY CLASS I OR CLASS II RESTRICTED T-CELL REACTIONS USING IMMUNOMODULATING, NON-CODING RNA MOTIVES
|
CA2480775C
(en)
*
|
2002-04-04 |
2016-05-31 |
Coley Pharmaceutical Gmbh |
Immunostimulatory g,u-containing oligoribonucleotides
|
US20030224013A1
(en)
*
|
2002-04-19 |
2003-12-04 |
Cole Garry T. |
Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
|
US20040009944A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Methylated immunostimulatory oligonucleotides and methods of using the same
|
US20040013649A1
(en)
*
|
2002-05-10 |
2004-01-22 |
Inex Pharmaceuticals Corporation |
Cancer vaccines and methods of using the same
|
MXPA04011127A
(es)
*
|
2002-05-10 |
2005-07-01 |
Inex Pharmaceuticals Corp |
Oligonucleotidos inmuno estimuladores metilados y metodos para utilizar los mismos.
|
US20040009943A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Pathogen vaccines and methods for using the same
|
KR100456681B1
(ko)
*
|
2002-05-22 |
2004-11-10 |
주식회사 대웅 |
박테리아의 염색체 dna 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
|
CA2388049A1
(en)
*
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
SE0201701D0
(sv)
*
|
2002-06-05 |
2002-06-05 |
Gotovax Ab |
Treatment of epithelial tumors and infections
|
US20040009949A1
(en)
*
|
2002-06-05 |
2004-01-15 |
Coley Pharmaceutical Group, Inc. |
Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
|
MXPA04011210A
(es)
*
|
2002-06-20 |
2005-02-14 |
Cytos Biotechnology Ag |
Particulares similares a virus empacadas para uso como adyuvantes: metodo de preparacion y uso.
|
JP2005535636A
(ja)
|
2002-06-28 |
2005-11-24 |
アメリカ合衆国 |
インターフェロンβおよびIL−2Rアンタゴニストを用いて自己免疫疾患を治療する方法
|
US20040053880A1
(en)
*
|
2002-07-03 |
2004-03-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
US7569553B2
(en)
*
|
2002-07-03 |
2009-08-04 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7605138B2
(en)
*
|
2002-07-03 |
2009-10-20 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7807803B2
(en)
*
|
2002-07-03 |
2010-10-05 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7576066B2
(en)
*
|
2002-07-03 |
2009-08-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
AU2003255969A1
(en)
*
|
2002-07-17 |
2004-02-02 |
Coley Pharmaceutical Gmbh |
Use of cpg nucleic acids in prion-disease
|
EP2011510B1
(en)
|
2002-07-18 |
2011-01-12 |
University of Washington |
Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
|
WO2004011650A2
(en)
|
2002-07-24 |
2004-02-05 |
Intercell Ag |
Antigens encoded by alternative reading frame from pathogenic viruses
|
US20060034854A1
(en)
|
2002-08-02 |
2006-02-16 |
Berthet Francois-Xavier J |
Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
|
ATE488246T1
(de)
|
2002-08-15 |
2010-12-15 |
3M Innovative Properties Co |
Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
|
AR040996A1
(es)
*
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
JP2006504687A
(ja)
|
2002-09-13 |
2006-02-09 |
インターツェル・アクチェンゲゼルシャフト |
C型肝炎ウイルスペプチドの単離方法
|
US20040106741A1
(en)
*
|
2002-09-17 |
2004-06-03 |
Kriesel Joshua W. |
Nanofilm compositions with polymeric components
|
US8263091B2
(en)
*
|
2002-09-18 |
2012-09-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
|
WO2004031382A1
(ja)
*
|
2002-10-02 |
2004-04-15 |
Mochida Pharmaceutical Co., Ltd. |
新規なモノクローナル抗体の作製方法
|
US8043622B2
(en)
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
CA2502414A1
(en)
|
2002-10-15 |
2004-04-29 |
Intercell Ag |
Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
|
NZ539509A
(en)
|
2002-10-23 |
2008-05-30 |
Glaxosmithkline Biolog Sa |
Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
|
WO2004037321A2
(en)
*
|
2002-10-25 |
2004-05-06 |
University Of Connecticut Health Center |
Immunotherapy of cancer through controlled cell lysis
|
CN1753687A
(zh)
*
|
2002-10-29 |
2006-03-29 |
科勒制药集团股份有限公司 |
Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
|
CA2504493C
(en)
*
|
2002-11-01 |
2015-12-29 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
|
ATE466875T1
(de)
|
2002-11-15 |
2010-05-15 |
Novartis Vaccines & Diagnostic |
Unerwartete oberflächenproteine in neisseria meningitidis
|
CN101955976A
(zh)
*
|
2002-11-21 |
2011-01-26 |
贝希尔治疗学股份有限公司 |
预防和治疗疾病的方法及免疫调节核酸组合物
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004053104A2
(en)
*
|
2002-12-11 |
2004-06-24 |
Coley Pharmaceutical Group, Inc. |
5’ cpg nucleic acids and methods of use
|
US20040213808A1
(en)
*
|
2002-12-11 |
2004-10-28 |
Michael Lieberman |
Recombinant vaccine against flavivirus infection
|
US20050287170A1
(en)
*
|
2002-12-11 |
2005-12-29 |
Hawaii Biotech, Inc. |
Subunit vaccine against West Nile viral infection
|
KR100525321B1
(ko)
*
|
2002-12-13 |
2005-11-02 |
안웅식 |
파필로마바이러스 항원 단백질 및CpG-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
|
CN100546998C
(zh)
|
2002-12-23 |
2009-10-07 |
戴纳伐克斯技术股份有限公司 |
免疫刺激序列寡核苷酸和使用方法
|
US8158768B2
(en)
|
2002-12-23 |
2012-04-17 |
Dynavax Technologies Corporation |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
AU2003302743B2
(en)
*
|
2002-12-23 |
2008-09-04 |
Dynavax Technologies Corporation |
Branched immunomodulatory compounds and methods of using the same
|
WO2004060396A2
(en)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenic compositions containing phospholpid
|
EP2572715A1
(en)
|
2002-12-30 |
2013-03-27 |
3M Innovative Properties Company |
Immunostimulatory Combinations
|
WO2004062599A2
(en)
|
2003-01-06 |
2004-07-29 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
EP1594956A4
(en)
|
2003-02-03 |
2007-08-01 |
Fraunhofer Usa Inc |
SYSTEM FOR EXPRESSION OF GENES IN PLANTS
|
WO2004071459A2
(en)
*
|
2003-02-13 |
2004-08-26 |
3M Innovative Properties Company |
Methods and compositions related to irm compounds and toll-like receptor 8
|
AU2004213855B2
(en)
|
2003-02-20 |
2010-03-04 |
University Of Connecticut Health Center |
Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
|
GB2398783A
(en)
|
2003-02-26 |
2004-09-01 |
Antonio Lanzavecchia |
A method for producing immortalised human B memory lymphocytes
|
EP1599726A4
(en)
*
|
2003-02-27 |
2009-07-22 |
3M Innovative Properties Co |
SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
|
AU2004218349A1
(en)
|
2003-03-04 |
2004-09-16 |
3M Innovative Properties Company |
Prophylactic treatment of UV-induced epidermal neoplasia
|
EP2287313A1
(en)
|
2003-03-04 |
2011-02-23 |
Intercell AG |
Streptococcus pyogenes antigens
|
JP2006520245A
(ja)
|
2003-03-13 |
2006-09-07 |
スリーエム イノベイティブ プロパティズ カンパニー |
入れ墨の除去方法
|
CA2517673C
(en)
|
2003-03-24 |
2013-08-13 |
Intercell Ag |
Improved vaccines for preventing viral infection
|
US20040192585A1
(en)
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
US7537767B2
(en)
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
EP1613775B1
(en)
*
|
2003-03-26 |
2012-08-29 |
Multicell Immunotherapeutics, Inc. |
Selected rna motifs in anti-leukemia therapy
|
BRPI0408623A
(pt)
|
2003-03-26 |
2006-03-07 |
Cytos Biotechnology Ag |
conjugados de partìcula semelhante ao vìrus análogo de peptìdeo de melan-a
|
JP2007523609A
(ja)
|
2003-03-31 |
2007-08-23 |
インターツェル・アクチェンゲゼルシャフト |
表皮ブドウ球菌抗原
|
WO2004087203A2
(en)
*
|
2003-04-02 |
2004-10-14 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatory nucleic acid oil-in-water formulations for topical application
|
CA2521682A1
(en)
*
|
2003-04-10 |
2004-12-16 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds using metal-containing particulate support materials
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
SE0301109D0
(sv)
*
|
2003-04-14 |
2003-04-14 |
Mallen Huang |
Nucleotide vaccine composition
|
AU2004230244B2
(en)
|
2003-04-15 |
2011-09-22 |
Intercell Ag |
S. pneumoniae antigens
|
WO2004096144A2
(en)
*
|
2003-04-28 |
2004-11-11 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
WO2004099242A2
(en)
|
2003-05-07 |
2004-11-18 |
Intercell Ag |
Streptococcus agalactiae antigens i + ii
|
WO2004100965A1
(ja)
*
|
2003-05-15 |
2004-11-25 |
Japan Science And Technology Agency |
免疫刺激剤
|
AU2004272972A1
(en)
|
2003-05-22 |
2005-03-24 |
Fraunhofer Usa, Inc. |
Recombinant carrier molecule for expression, delivery and purification of target polypeptides
|
WO2004106367A2
(en)
|
2003-05-30 |
2004-12-09 |
Intercell Ag |
Enterococcus antigens
|
CA2528007C
(en)
|
2003-06-02 |
2012-03-27 |
Chiron Corporation |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
WO2005000884A1
(en)
|
2003-06-05 |
2005-01-06 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
|
EP1635846A4
(en)
*
|
2003-06-20 |
2009-01-28 |
Coley Pharm Gmbh |
SMALL MOLECULAR TLR (TOLL-LIKE RECEPTOR) ANTAGONISTS
|
US20060251623A1
(en)
*
|
2003-07-10 |
2006-11-09 |
Caytos Biotechnology Ag |
Packaged virus-like particles
|
US20050013812A1
(en)
*
|
2003-07-14 |
2005-01-20 |
Dow Steven W. |
Vaccines using pattern recognition receptor-ligand:lipid complexes
|
JP2007501252A
(ja)
*
|
2003-08-05 |
2007-01-25 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調整剤を含有する製剤
|
AR045260A1
(es)
*
|
2003-08-12 |
2005-10-19 |
3M Innovative Properties Co |
Compuestos que contienen imidazo-oxima sustituidos
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
WO2005018574A2
(en)
*
|
2003-08-25 |
2005-03-03 |
3M Innovative Properties Company |
Immunostimulatory combinations and treatments
|
AR045529A1
(es)
*
|
2003-08-27 |
2005-11-02 |
3M Innovative Properties Co |
Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi
|
US20060216333A1
(en)
*
|
2003-09-02 |
2006-09-28 |
Miller Richard L |
Methods related to the treatment of mucosal associated conditions
|
US20050054665A1
(en)
*
|
2003-09-05 |
2005-03-10 |
3M Innovative Properties Company |
Treatment for CD5+ B cell lymphoma
|
JP2007505147A
(ja)
|
2003-09-12 |
2007-03-08 |
アンティジェニクス インコーポレーテッド |
単純ヘルペスウイルス感染の治療および予防用ワクチン
|
US7615539B2
(en)
*
|
2003-09-25 |
2009-11-10 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid-lipophilic conjugates
|
US8574596B2
(en)
|
2003-10-02 |
2013-11-05 |
Glaxosmithkline Biologicals, S.A. |
Pertussis antigens and use thereof in vaccination
|
CN1897948A
(zh)
*
|
2003-10-03 |
2007-01-17 |
3M创新有限公司 |
烷氧基取代的咪唑并喹啉
|
US7544697B2
(en)
*
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
US20090075980A1
(en)
*
|
2003-10-03 |
2009-03-19 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and Analogs Thereof
|
CA2542099A1
(en)
*
|
2003-10-11 |
2005-04-21 |
Inex Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
SG122973A1
(en)
*
|
2003-10-30 |
2006-06-29 |
Coley Pharm Gmbh |
C-class oligonucleotide analogs with enhanced immunostimulatory potency
|
US20050239733A1
(en)
*
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
WO2005041891A2
(en)
*
|
2003-10-31 |
2005-05-12 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
US20050100983A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Coley Pharmaceutical Gmbh |
Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
|
EP1685129A4
(en)
|
2003-11-14 |
2008-10-22 |
3M Innovative Properties Co |
OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
|
US8598192B2
(en)
*
|
2003-11-14 |
2013-12-03 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazoquinolines
|
JP4891088B2
(ja)
*
|
2003-11-25 |
2012-03-07 |
スリーエム イノベイティブ プロパティズ カンパニー |
置換されたイミダゾ環系および方法
|
US20050287118A1
(en)
*
|
2003-11-26 |
2005-12-29 |
Epitomics, Inc. |
Bacterial plasmid with immunological adjuvant function and uses thereof
|
US20050277127A1
(en)
*
|
2003-11-26 |
2005-12-15 |
Epitomics, Inc. |
High-throughput method of DNA immunogen preparation and immunization
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
US8940755B2
(en)
*
|
2003-12-02 |
2015-01-27 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
CA2551560A1
(en)
|
2003-12-23 |
2005-07-14 |
Arbor Vita Corporation |
Antibodies for oncogenic strains of hpv and methods of their use
|
JP4817599B2
(ja)
*
|
2003-12-25 |
2011-11-16 |
独立行政法人科学技術振興機構 |
免疫活性増強剤とこれを用いた免疫活性の増強方法
|
JP2007517035A
(ja)
*
|
2003-12-29 |
2007-06-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
|
EP1699398A4
(en)
*
|
2003-12-30 |
2007-10-17 |
3M Innovative Properties Co |
IMPROVING THE IMMUNE RESPONSE
|
US8735421B2
(en)
*
|
2003-12-30 |
2014-05-27 |
3M Innovative Properties Company |
Imidazoquinolinyl sulfonamides
|
WO2005072290A2
(en)
*
|
2004-01-23 |
2005-08-11 |
Joslin Diabetes Center |
Methods of treating, reducing, or preventing autoimmune conditions
|
EP1730182B1
(en)
|
2004-02-05 |
2015-04-29 |
The Ohio State University Research Foundation |
Chimeric vegf peptides
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
EP1720568A2
(en)
|
2004-02-19 |
2006-11-15 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory viral rna oligonucleotides
|
US20050208482A1
(en)
*
|
2004-03-16 |
2005-09-22 |
Cohen David I |
Tat-based immunomodulatory compositions and methods for their discovery and use
|
US7820175B2
(en)
|
2004-03-19 |
2010-10-26 |
Herbal Spring, Llc |
Herbal therapy for the treatment of food allergy
|
EP1730143A2
(en)
*
|
2004-03-24 |
2006-12-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
TWI235440B
(en)
*
|
2004-03-31 |
2005-07-01 |
Advanced Semiconductor Eng |
Method for making leadless semiconductor package
|
EP1735010A4
(en)
*
|
2004-04-09 |
2008-08-27 |
3M Innovative Properties Co |
METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI)
|
US20060051374A1
(en)
*
|
2004-04-28 |
2006-03-09 |
3M Innovative Properties Company |
Compositions and methods for mucosal vaccination
|
US8895521B2
(en)
|
2004-05-06 |
2014-11-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for the treatment of uveitis
|
AU2005285513B2
(en)
|
2004-05-25 |
2011-02-24 |
Oregon Health And Science University |
SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
|
HUE026644T2
(en)
|
2004-05-28 |
2016-07-28 |
Oryxe |
Mixture for transdermal administration of low and high molecular weight compounds
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
WO2005123080A2
(en)
*
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
WO2006009832A1
(en)
*
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
WO2006038923A2
(en)
*
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
WO2006065280A2
(en)
*
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
WO2006009826A1
(en)
*
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
KR100958505B1
(ko)
*
|
2004-07-18 |
2010-05-17 |
씨에스엘 리미티드 |
면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
|
AU2005270918B2
(en)
|
2004-08-03 |
2011-03-03 |
Innate Pharma S.A. |
Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2006026470A2
(en)
*
|
2004-08-27 |
2006-03-09 |
3M Innovative Properties Company |
Hiv immunostimulatory compositions
|
US20090270443A1
(en)
*
|
2004-09-02 |
2009-10-29 |
Doris Stoermer |
1-amino imidazo-containing compounds and methods
|
KR101508563B1
(ko)
|
2004-09-22 |
2015-04-07 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
|
EP2149583B1
(en)
|
2004-09-24 |
2015-10-28 |
Novartis AG |
Modified VP1-capsid protein of parvovirus B19
|
JP2008000001A
(ja)
*
|
2004-09-30 |
2008-01-10 |
Osaka Univ |
免疫刺激オリゴヌクレオチドおよびその医薬用途
|
EP1804583A4
(en)
*
|
2004-10-08 |
2009-05-20 |
3M Innovative Properties Co |
ADJUVANT FOR DNA VACCINE
|
DK3312272T3
(da)
|
2004-10-08 |
2019-12-02 |
Us Gov Health & Human Services |
Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
|
MY159370A
(en)
*
|
2004-10-20 |
2016-12-30 |
Coley Pharm Group Inc |
Semi-soft-class immunostimulatory oligonucleotides
|
WO2006065549A2
(en)
|
2004-12-03 |
2006-06-22 |
Medical University Of Ohio |
Attenuated vaccine useful for immunizations against coccidioides spp. infections
|
WO2006063072A2
(en)
*
|
2004-12-08 |
2006-06-15 |
3M Innovative Properties Company |
Immunomodulatory compositions, combinations and methods
|
US9809824B2
(en)
*
|
2004-12-13 |
2017-11-07 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
CA2594253C
(en)
|
2004-12-30 |
2015-08-11 |
3M Innovative Properties Company |
Treatment for cutaneous metastases
|
EP1831226B1
(en)
|
2004-12-30 |
2012-08-08 |
3M Innovative Properties Company |
Chiral tetracyclic compounds inducing interferon biosynthesis
|
US8034938B2
(en)
|
2004-12-30 |
2011-10-11 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
CA2590974C
(en)
|
2005-01-27 |
2017-10-03 |
Children's Hospital & Research Center At Oakland |
Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
|
WO2006084251A2
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune reponse modifiers
|
WO2006086634A2
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
AU2006216493A1
(en)
*
|
2005-02-24 |
2006-08-31 |
Coley Pharmaceutical Gmbh |
Immunostimulatory oligonucleotides
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US8101345B1
(en)
|
2005-03-25 |
2012-01-24 |
Isis Pharmaceuticals, Inc. |
Proinflammatory nucleic acids
|
SG158145A1
(en)
|
2005-03-31 |
2010-01-29 |
Glaxosmithkline Biolog Sa |
Vaccines against chlamydial infection
|
AU2006232375A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
CA2602683A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
WO2006110656A2
(en)
*
|
2005-04-08 |
2006-10-19 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of viral infections and other medical disorders
|
EP1868628B1
(en)
|
2005-04-08 |
2014-06-11 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of poxvirus infections
|
SG161260A1
(en)
*
|
2005-04-08 |
2010-05-27 |
Coley Pharm Group Inc |
Methods for treating infectious disease exacerbated asthma
|
US20080193474A1
(en)
*
|
2005-04-25 |
2008-08-14 |
Griesgraber George W |
Immunostimulatory Compositions
|
AU2006241149A1
(en)
*
|
2005-04-26 |
2006-11-02 |
Coley Pharmaceutical Gmbh |
Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
|
EP2457926B1
(en)
|
2005-04-29 |
2014-09-24 |
GlaxoSmithKline Biologicals S.A. |
Novel method for preventing or treating M. tuberculosis infection
|
KR101365538B1
(ko)
|
2005-06-14 |
2014-02-21 |
프로톡스 테라페유틱 인코포레이티드 |
변형된 포어 형성 단백질을 이용하여 양성 전립선 비대를치료하거나 예방하는 방법
|
JP5222134B2
(ja)
|
2005-06-15 |
2013-06-26 |
ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション |
Her−2ペプチド
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
SI2179737T1
(sl)
|
2005-07-01 |
2014-02-28 |
Index Pharmaceuticals Ab |
Modulacija reakcije na stereoide
|
DK2380584T3
(da)
|
2005-07-01 |
2014-01-20 |
Index Pharmaceuticals Ab |
Immunstimulerende fremgangsmåde
|
SG163583A1
(en)
*
|
2005-07-07 |
2010-08-30 |
Coley Pharm Group Inc |
Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
|
US20080206276A1
(en)
|
2005-07-08 |
2008-08-28 |
Michael Otto |
Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
|
AU2006268333B2
(en)
|
2005-07-11 |
2012-06-14 |
Globeimmune, Inc. |
Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
|
BRPI0614475B8
(pt)
|
2005-08-03 |
2021-05-25 |
Fraunhofer Usa Inc |
polipeptídeo, anticorpo, ácido nucleico, vetores, célula hospedeira, composição e processos de produção de anticorpo
|
US20100130425A1
(en)
|
2005-09-09 |
2010-05-27 |
Oregon Health & Science University |
Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
|
EA013468B1
(ru)
*
|
2005-09-16 |
2010-04-30 |
Коли Фармасьютикал Гмбх |
Иммуностимулирующая одноцепочечная рибонуклеиновая кислота с фосфодиэфирным остовом
|
EP1924692A2
(en)
*
|
2005-09-16 |
2008-05-28 |
Coley Pharmaceutical GmbH |
Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
|
WO2007041190A2
(en)
*
|
2005-09-30 |
2007-04-12 |
The University Of Iowa Research Foundation |
Polymer-based delivery system for immunotherapy of cancer
|
JP2009513629A
(ja)
|
2005-10-28 |
2009-04-02 |
インデックス・ファーマシューティカルズ・アクチエボラーグ |
炎症性疾患を予防、処置、および/または緩和する組成物および方法
|
EP1957647B1
(en)
|
2005-11-25 |
2015-03-04 |
Zoetis Belgium S.A. |
Immunostimulatory oligoribonucleotides
|
SI2347775T1
(sl)
|
2005-12-13 |
2020-10-30 |
President And Fellows Of Harvard College |
Ogrodja za celično transplantacijo
|
AU2006325225B2
(en)
|
2005-12-14 |
2013-07-04 |
Cytos Biotechnology Ag |
Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
|
CA2816182C
(en)
|
2005-12-22 |
2018-02-20 |
Glaxosmithkline Biologicals S.A. |
Pneumococcal polysaccharide conjugate vaccine
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US9259463B2
(en)
|
2006-01-16 |
2016-02-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Chlamydia vaccine
|
ZA200805602B
(en)
|
2006-01-17 |
2009-12-30 |
Arne Forsgren |
A novel surface exposed haemophilus influenzae protein (protein E; pE)
|
KR20080106433A
(ko)
|
2006-02-13 |
2008-12-05 |
프라운호퍼 유에스에이, 인코포레이티드 |
인플루엔자 항원, 백신 조성물 및 관련 방법
|
ES2553284T5
(es)
|
2006-02-15 |
2021-08-31 |
Rechtsanwalt Thomas Beck |
Composiciones y procedimientos para formulaciones de oligonucleótidos
|
US8951528B2
(en)
*
|
2006-02-22 |
2015-02-10 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
EP2253957B1
(en)
|
2006-03-14 |
2013-05-15 |
Oregon Health and Science University |
Methods for producing an immune response to tuberculosis.
|
US20100021503A1
(en)
|
2006-03-30 |
2010-01-28 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
WO2007119815A1
(ja)
|
2006-04-14 |
2007-10-25 |
Kyowa Hakko Kirin Co., Ltd. |
Toll様受容体9作動薬
|
EP2034015B1
(en)
|
2006-05-31 |
2012-07-11 |
Toray Industries, Inc. |
Immunostimulatory oligonucleotide and pharmaceutical application thereof
|
EP2390359A1
(en)
|
2006-06-02 |
2011-11-30 |
GlaxoSmithKline Biologicals S.A. |
Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the ICOS gene
|
KR100906970B1
(ko)
|
2006-06-03 |
2009-07-10 |
주식회사 바이오씨에스 |
피부 면역질환에 대한 CpG 올리고데옥시뉴클레오티드의치료학적 용도
|
WO2007143582A2
(en)
*
|
2006-06-05 |
2007-12-13 |
Baylor College Of Medicine |
Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
|
RU2476595C2
(ru)
|
2006-06-12 |
2013-02-27 |
Цитос Биотехнологи Аг |
Способы упаковки олигонуклеотидов в вирусоподобные частицы рнк-содержащих бактериофагов
|
CA2654709A1
(en)
|
2006-06-12 |
2007-12-21 |
Nathalie Devos |
Neisseria meningitidis lipooligosaccharide vaccine
|
JP2009542196A
(ja)
|
2006-07-07 |
2009-12-03 |
インターセル アーゲー |
小型の化膿連鎖球菌抗原およびそれらの使用
|
US8153116B2
(en)
|
2006-07-11 |
2012-04-10 |
University Of Connecticut |
Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
|
WO2008094183A2
(en)
*
|
2006-07-11 |
2008-08-07 |
University Of Connecticut |
Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
|
US7906506B2
(en)
*
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
DE102006035618A1
(de)
*
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
|
JP2010507361A
(ja)
|
2006-07-31 |
2010-03-11 |
キュアバック ゲーエムベーハー |
具体的には免疫刺激剤/アジュバントとしての、一般式(I):GlXmGn、または一般式(II):ClXmCnで表される核酸
|
EP2066344B2
(en)
|
2006-09-07 |
2016-06-29 |
GlaxoSmithKline Biologicals S.A. |
Inactivated Poliovirus combination vaccine
|
CA2661224A1
(en)
|
2006-09-15 |
2008-03-20 |
Intercell Ag |
Borrelia antigens
|
SI2068918T1
(sl)
|
2006-09-26 |
2012-09-28 |
Infectious Disease Res Inst |
Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
PT2078080E
(pt)
|
2006-09-27 |
2015-09-18 |
Coley Pharm Gmbh |
Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
|
US20100144846A1
(en)
*
|
2006-10-26 |
2010-06-10 |
Coley Pharmaceutical Gmbh |
Oligoribonucleotides and uses thereof
|
DK2444807T3
(da)
|
2006-11-01 |
2014-08-11 |
Ventana Med Syst Inc |
Mono- og dinitropyrazolhaptenkonjugater
|
US20090142362A1
(en)
*
|
2006-11-06 |
2009-06-04 |
Avant Immunotherapeutics, Inc. |
Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
|
CN104857512A
(zh)
*
|
2006-11-09 |
2015-08-26 |
戴纳瓦克斯技术公司 |
使用免疫刺激性寡核苷酸进行长期的疾病修饰
|
EP1923069A1
(en)
|
2006-11-20 |
2008-05-21 |
Intercell AG |
Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
|
US20080149123A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
EP2266591A3
(en)
|
2007-01-12 |
2012-08-08 |
Intercell AG |
Protective proteins of S. agalactiae, combinations thereof and methods of using the same
|
WO2008106551A2
(en)
|
2007-02-28 |
2008-09-04 |
The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. |
Brachyury polypeptides and methods for use
|
HUE031411T2
(en)
|
2007-03-02 |
2017-07-28 |
Glaxosmithkline Biologicals Sa |
New Methods and Preparations
|
AU2008222523A1
(en)
*
|
2007-03-07 |
2008-09-12 |
Nventa Biopharmaceuticals Corporation |
Double-stranded locked nucleic acid compositions
|
JP5579451B2
(ja)
|
2007-03-19 |
2014-08-27 |
グローブイミューン,インコーポレイテッド |
ガンのための標的化治療の変異性回避の標的化アブレーションのための組成物
|
MX2009010800A
(es)
|
2007-04-04 |
2010-01-29 |
Infectious Disease Res Inst Id |
Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
|
AR066405A1
(es)
|
2007-04-20 |
2009-08-19 |
Glaxosmithkline Biolog Sa |
Vacuna
|
CA2685558A1
(en)
|
2007-04-28 |
2008-11-06 |
Fraunhofer Usa, Inc. |
Trypanosoma antigens, vaccine compositions, and related methods
|
JP2010525035A
(ja)
|
2007-05-02 |
2010-07-22 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ワクチン
|
CN102015754A
(zh)
|
2007-05-02 |
2011-04-13 |
英特塞尔股份公司 |
克雷伯菌(Klebsiella)抗原
|
US8309529B2
(en)
*
|
2007-05-04 |
2012-11-13 |
Index Pharmaceuticals Ab |
Tumour growth inhibitory compounds and methods of their use
|
EP2160199A2
(en)
|
2007-05-17 |
2010-03-10 |
Coley Pharmaceutical Group, Inc. |
Class a oligonucleotides with immunostimulatory potency
|
WO2008142513A2
(en)
*
|
2007-05-18 |
2008-11-27 |
Coley Pharmaceutical Gmbh |
Phosphate-modified oligonucleotide analogs with immunostimulatory activity
|
DK2167963T3
(da)
|
2007-05-23 |
2019-06-24 |
Ventana Med Syst Inc |
Polymerbærere til immunhistokemi og in situ-hybridisering
|
EA201300101A1
(ru)
|
2007-05-24 |
2014-02-28 |
Глаксосмитклайн Байолоджикалс С.А. |
Лиофилизированная антигенная композиция
|
DK2158211T3
(en)
|
2007-05-31 |
2016-12-05 |
Medigene Ag |
Mutated structural protein of a parvovirus
|
EP2012122A1
(en)
|
2007-07-06 |
2009-01-07 |
Medigene AG |
Mutated parvovirus structural proteins as vaccines
|
AU2008265218A1
(en)
|
2007-06-18 |
2008-12-24 |
Intercell Ag |
Chlamydia antigens
|
KR101579947B1
(ko)
|
2007-06-26 |
2015-12-28 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
|
ES2725450T3
(es)
|
2007-07-02 |
2019-09-24 |
Etubics Corp |
Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
|
CA2692933C
(en)
|
2007-07-11 |
2016-10-18 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
CN101795709B
(zh)
|
2007-08-02 |
2013-07-17 |
彼昂德瓦克斯医药有限公司 |
多亚基多表位流感疫苗
|
WO2009020553A2
(en)
|
2007-08-03 |
2009-02-12 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
US7879812B2
(en)
|
2007-08-06 |
2011-02-01 |
University Of Iowa Research Foundation |
Immunomodulatory oligonucleotides and methods of use therefor
|
KR20100068390A
(ko)
|
2007-08-13 |
2010-06-23 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신
|
BRPI0814899A2
(pt)
*
|
2007-08-21 |
2015-02-03 |
Dynavax Tech Corp |
Composição, vacina, metodo para amenizar um ou mais sintomas associados à infecção com o virus da influenza em um individuo e método para reduzir a probabilidade de infecção com o virus da influeza em um individuo"
|
US9370531B2
(en)
*
|
2007-08-31 |
2016-06-21 |
New York University |
Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
US9050280B2
(en)
|
2007-09-17 |
2015-06-09 |
Mdxhealth Sa |
Methylation detection of MGMT
|
KR20100068422A
(ko)
|
2007-10-09 |
2010-06-23 |
콜리 파마슈티칼 게엠베하 |
변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
|
SG10201605208QA
(en)
|
2007-11-07 |
2016-08-30 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
|
JP2011514881A
(ja)
|
2007-11-09 |
2011-05-12 |
ザ ソルク インスティテュート フォー バイオロジカル スタディーズ |
免疫増強剤としてのtam受容体阻害剤の使用および免疫抑制剤としてのtam活性化剤の使用
|
AU2008331800A1
(en)
|
2007-12-03 |
2009-06-11 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
WO2009076158A1
(en)
|
2007-12-07 |
2009-06-18 |
Novartis Ag |
Compositions for inducing immune responses
|
EP4219566A3
(en)
|
2007-12-24 |
2023-09-06 |
ID Biomedical Corporation of Quebec |
Recombinant rsv antigens
|
WO2009094190A2
(en)
*
|
2008-01-25 |
2009-07-30 |
Chimerix, Inc. |
Methods of treating viral infections
|
SG188104A1
(en)
|
2008-01-31 |
2013-03-28 |
Curevac Gmbh |
Nucleic acids comprising formula (nuglxmgnnv)a and derivatives thereof as an immunostimulating agents /adjuvants
|
AU2009215188B2
(en)
|
2008-02-13 |
2014-09-18 |
Dana-Farber Cancer Institute, Inc. |
Continuous cell programming devices
|
WO2009105641A2
(en)
*
|
2008-02-20 |
2009-08-27 |
New York University |
Preventing and treating amyloid-beta deposition by stimulation of innate immunity
|
AU2009223613B2
(en)
|
2008-03-10 |
2014-09-25 |
Children's Hospital & Research Center At Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
BRPI0909664A2
(pt)
|
2008-03-17 |
2019-09-24 |
Intercell Ag |
peptídios protetores contra s. pneumoniae e composições, métodos e usos relacionados com os mesmos
|
US9527906B2
(en)
|
2008-04-18 |
2016-12-27 |
The General Hospital Corporation |
Immunotherapies employing self-assembling vaccines
|
WO2009140626A2
(en)
|
2008-05-15 |
2009-11-19 |
Dynavax Technologies Corporation |
Long term disease modification using immunostimulatory oligonucleotides
|
WO2009143292A2
(en)
|
2008-05-21 |
2009-11-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating pneumoconiosis with oligodeoxynucleotides
|
US8877208B2
(en)
|
2008-05-23 |
2014-11-04 |
The Regents Of The University Of Michigan |
Multivalent nanoemulsion vaccines
|
CA2720728C
(en)
|
2008-06-05 |
2018-04-03 |
Ventana Medical Systems, Inc. |
Compositions comprising nanomaterials and method for using such compositions for histochemical processes
|
TWI351288B
(en)
*
|
2008-07-04 |
2011-11-01 |
Univ Nat Pingtung Sci & Tech |
Cpg dna adjuvant in avian vaccines
|
CA2733356C
(en)
|
2008-08-01 |
2016-06-07 |
Gamma Vaccines Pty Limited |
Influenza vaccines
|
EP2353008A2
(en)
|
2008-09-22 |
2011-08-10 |
Oregon Health and Science University |
Methods for detecting a mycobacterium tuberculosis infection
|
US20100092526A1
(en)
|
2008-09-26 |
2010-04-15 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
WO2010037046A1
(en)
|
2008-09-28 |
2010-04-01 |
Fraunhofer Usa, Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
CA2737352C
(en)
*
|
2008-10-16 |
2017-06-27 |
University Of Saskatchewan |
Combination adjuvant formulation
|
US9732324B2
(en)
|
2008-10-23 |
2017-08-15 |
Cornell University |
Anti-viral method
|
WO2010048731A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Christopher John Ong |
Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents
|
WO2010057197A1
(en)
|
2008-11-17 |
2010-05-20 |
The Regents Of The University Of Michigan |
Cancer vaccine compositions and methods of using the same
|
EP2398466B1
(en)
|
2008-11-24 |
2021-02-17 |
Massachusetts Institute of Technology |
Methods and compositions for localized nanoparticle delivery to a tumor
|
KR101881596B1
(ko)
|
2008-12-02 |
2018-07-24 |
웨이브 라이프 사이언시스 재팬 인코포레이티드 |
인 원자 변형된 핵산의 합성 방법
|
EP2356225A1
(en)
|
2008-12-03 |
2011-08-17 |
Protea Vaccine Technologies Ltd. |
GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
|
EP2374813A1
(en)
|
2008-12-03 |
2011-10-12 |
Proyecto de Biomedicina Cima, S.L. |
Use of phenol-soluble modulins for vaccine development
|
US8552165B2
(en)
*
|
2008-12-09 |
2013-10-08 |
Heather Davis |
Immunostimulatory oligonucleotides
|
ES2622562T3
(es)
|
2008-12-09 |
2017-07-06 |
Pfizer Vaccines Llc |
Vacuna de péptido CH3 de IgE
|
EP2376107B1
(en)
|
2008-12-09 |
2014-05-21 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory oligonucleotides
|
AU2010203223B9
(en)
|
2009-01-05 |
2015-10-08 |
Epitogenesis Inc. |
Adjuvant compositions and methods of use
|
ES2536747T3
(es)
|
2009-01-20 |
2015-05-28 |
Transgene Sa |
ICAM 1 soluble como biomarcador para predicción de respuesta terapéutica
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
EP2424882A2
(en)
|
2009-02-05 |
2012-03-07 |
Intercell AG |
Peptides protective against e. faecalis, methods and uses relating thereto
|
EP2405938A2
(en)
|
2009-02-13 |
2012-01-18 |
Intercell AG |
Nontypable haemophilus influenzae antigens
|
WO2010099472A2
(en)
|
2009-02-27 |
2010-09-02 |
The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services |
Spanx-b polypeptides and their use
|
CN102575284A
(zh)
|
2009-03-17 |
2012-07-11 |
MDx健康公司 |
改进的基因表达检测
|
US8530431B2
(en)
|
2009-03-23 |
2013-09-10 |
Pin Pharma, Inc. |
Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
|
NZ595290A
(en)
|
2009-03-24 |
2012-09-28 |
Transgene Sa |
Biomarker for monitoring patients
|
WO2010115118A2
(en)
|
2009-04-03 |
2010-10-07 |
Antigenics, Inc. |
Methods for preparing and using multichaperone-antigen complexes
|
NZ594896A
(en)
|
2009-04-17 |
2013-07-26 |
Transgene Sa |
Biomarker for monitoring patients
|
EA201101530A1
(ru)
*
|
2009-04-21 |
2012-03-30 |
Селекта Байосайенсиз, Инк. |
ИММУНОНАНОТЕРАПИЯ, ОБЕСПЕЧИВАЮЩАЯ Th1-СМЕЩЕННЫЙ ОТВЕТ
|
RU2536248C2
(ru)
|
2009-04-30 |
2014-12-20 |
Коули Фармасьютикал Груп, Инк. |
Пневмококковая вакцина и ее применения
|
AU2010254551B2
(en)
|
2009-05-27 |
2016-10-20 |
Selecta Biosciences, Inc. |
Immunomodulatory agent-polymeric compounds
|
MA33409B1
(fr)
|
2009-05-27 |
2012-07-03 |
Glaxosmithkline Biolog Sa |
Produits de recombinaisoon de casb7439
|
EP2437753B1
(en)
|
2009-06-05 |
2016-08-31 |
Infectious Disease Research Institute |
Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
|
EP2442827B1
(en)
|
2009-06-16 |
2016-01-06 |
The Regents of the University of Michigan |
Nanoemulsion vaccines
|
MX2012000036A
(es)
|
2009-06-24 |
2012-02-28 |
Glaxosmithkline Biolog Sa |
Vacuna.
|
AU2010264688A1
(en)
|
2009-06-24 |
2012-01-19 |
Glaxosmithkline Biologicals S.A. |
Recombinant RSV antigens
|
IN2012DN00720A
(xx)
|
2009-07-06 |
2015-06-19 |
Ontorii Inc |
|
DK2452194T3
(en)
|
2009-07-10 |
2015-11-30 |
Transgene Sa |
Biomarker PATIENT SELECTION AND RELATED PRACTICES
|
CN105214080A
(zh)
|
2009-07-15 |
2016-01-06 |
诺华股份有限公司 |
Rsv f蛋白组合物和其制作方法
|
US8614200B2
(en)
|
2009-07-21 |
2013-12-24 |
Chimerix, Inc. |
Compounds, compositions and methods for treating ocular conditions
|
JP2013500326A
(ja)
|
2009-07-30 |
2013-01-07 |
ファイザー バクシーンズ エルエルシー |
抗原性タウペプチドおよびその使用
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
US20120190634A1
(en)
|
2009-08-26 |
2012-07-26 |
Rna Inc. |
Lipoteichoic acid-derived glycolipids, and compositions comprising same
|
WO2011026111A1
(en)
|
2009-08-31 |
2011-03-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Oral delivery of a vaccine to the large intestine to induce mucosal immunity
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
PE20161551A1
(es)
|
2009-09-03 |
2017-01-18 |
Pfizer Vaccines Llc |
Vacuna de pcsk9
|
US20110229437A1
(en)
*
|
2009-09-17 |
2011-09-22 |
Mutual Pharmaceutical Company, Inc. |
Method of Treating Asthma with Antiviral Agents
|
GB0917457D0
(en)
|
2009-10-06 |
2009-11-18 |
Glaxosmithkline Biolog Sa |
Method
|
WO2011041391A1
(en)
|
2009-09-29 |
2011-04-07 |
Fraunhofer Usa, Inc. |
Influenza hemagglutinin antibodies, compositions, and related methods
|
AU2010305273B2
(en)
|
2009-10-07 |
2016-09-29 |
Uvic Industry Partnerships Inc. |
Vaccines comprising heat-sensitive transgenes
|
EP2308896A1
(en)
|
2009-10-09 |
2011-04-13 |
Sanofi-aventis |
Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
|
EP2319871A1
(en)
|
2009-11-05 |
2011-05-11 |
Sanofi-aventis |
Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
|
JP2013507115A
(ja)
|
2009-10-09 |
2013-03-04 |
サノフイ |
「終末糖化産物受容体」への結合のためのポリペプチド、さらにはそれを含む組成物及び方法
|
US9181306B2
(en)
|
2009-10-16 |
2015-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
CN102713629B
(zh)
|
2009-11-20 |
2016-02-24 |
俄勒冈健康科学大学 |
用于检测结核分枝杆菌感染的方法
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
CA2785585A1
(en)
|
2009-12-22 |
2011-06-30 |
Celldex Therapeutics, Inc. |
Vaccine compositions
|
FR2954703B1
(fr)
|
2009-12-28 |
2013-12-13 |
Chu Nantes |
Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
|
HUE032860T2
(en)
|
2010-02-12 |
2017-11-28 |
Chimerix Inc |
A method for treating a virus infection
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
WO2011109422A2
(en)
|
2010-03-02 |
2011-09-09 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for the treatment of cancer
|
EA201290876A1
(ru)
|
2010-03-05 |
2013-03-29 |
Президент Энд Феллоуз Оф Гарвард Колледж |
Композиции индуцированных дендритных клеток и их использование
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
JP2013521770A
(ja)
|
2010-03-10 |
2013-06-13 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ワクチン組成物
|
WO2011112599A2
(en)
|
2010-03-12 |
2011-09-15 |
The United States Of America, As Represented By The Secretary. Department Of Health & Human Services |
Immunogenic pote peptides and methods of use
|
US20110229556A1
(en)
*
|
2010-03-19 |
2011-09-22 |
Massachusetts Institute Of Technology |
Lipid-coated polymer particles for immune stimulation
|
US9149432B2
(en)
|
2010-03-19 |
2015-10-06 |
Massachusetts Institute Of Technology |
Lipid vesicle compositions and methods of use
|
CN102917690B
(zh)
*
|
2010-03-19 |
2016-08-24 |
麻省理工学院 |
脂质囊泡组合物和使用方法
|
GB201005005D0
(en)
*
|
2010-03-25 |
2010-05-12 |
Angeletti P Ist Richerche Bio |
New vaccine
|
US9827300B2
(en)
|
2010-03-30 |
2017-11-28 |
Children's Hospital & Research Center Oakland |
Factor H binding proteins (FHBP) with altered properties and methods of use thereof
|
JP6002659B2
(ja)
|
2010-04-13 |
2016-10-05 |
セルデックス・セラピューティクス・インコーポレイテッド |
ヒトcd27に結合する抗体およびその使用
|
WO2011139709A2
(en)
|
2010-04-26 |
2011-11-10 |
Chimerix, Inc. |
Methods of treating retroviral infections and related dosage regimes
|
SI2772265T1
(en)
|
2010-05-14 |
2018-06-29 |
Oregon Health & Science University |
HCMV AND RHCMV RECOMBINANT VECTORS AND THEIR APPLICATIONS
|
NO2575876T3
(xx)
|
2010-05-26 |
2018-05-05 |
|
|
MX347471B
(es)
|
2010-05-28 |
2017-04-24 |
Zoetis Belgium S A |
Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
|
CA2800774A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
BR112013002298A2
(pt)
|
2010-07-30 |
2016-05-24 |
Curevac Gmbh |
complexação de ácidos nucleicos com componentes catiônicos reticulados com dissulfeto para transfecção e estimulação imunológica.
|
LT2753352T
(lt)
|
2010-09-03 |
2017-05-25 |
Valneva Austria Gmbh |
Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
|
AR082925A1
(es)
|
2010-09-08 |
2013-01-16 |
Medigene Ag |
Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
WO2012036993A1
(en)
|
2010-09-14 |
2012-03-22 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Computationally optimized broadly reactive antigens for influenza
|
US10428019B2
(en)
|
2010-09-24 |
2019-10-01 |
Wave Life Sciences Ltd. |
Chiral auxiliaries
|
MX354752B
(es)
|
2010-09-27 |
2018-03-20 |
Janssen Vaccines & Prevention Bv |
Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
|
PT2624873T
(pt)
|
2010-10-06 |
2020-03-04 |
Harvard College |
Hidrogéis injectáveis formadores de poros para terapias celulares à base de materiais
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
EP2640190A4
(en)
|
2010-11-05 |
2016-05-11 |
Selecta Biosciences Inc |
MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
|
EP2637687B1
(en)
|
2010-11-08 |
2021-01-06 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
PL2651436T3
(pl)
|
2010-12-14 |
2016-10-31 |
|
Kompozycja antygenów mykobakteryjnych
|
AU2012211043B2
(en)
|
2011-01-27 |
2017-04-06 |
Gamma Vaccines Pty Limited |
Combination vaccines
|
CN103517713A
(zh)
|
2011-02-22 |
2014-01-15 |
彼昂德瓦克斯医药有限公司 |
在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
EA027236B1
(ru)
|
2011-04-08 |
2017-07-31 |
Иммьюн Дизайн Корп. |
Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
|
TW201302779A
(zh)
|
2011-04-13 |
2013-01-16 |
Glaxosmithkline Biolog Sa |
融合蛋白質及組合疫苗
|
US20120288515A1
(en)
|
2011-04-27 |
2012-11-15 |
Immune Design Corp. |
Synthetic long peptide (slp)-based vaccines
|
FR2975600B1
(fr)
|
2011-05-24 |
2013-07-05 |
Assist Publ Hopitaux De Paris |
Agents pour le traitement de tumeurs
|
WO2012167046A1
(en)
|
2011-06-01 |
2012-12-06 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
CA2837207A1
(en)
|
2011-06-01 |
2012-12-06 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
CA2838158C
(en)
|
2011-06-03 |
2019-07-16 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
BR112013031039B1
(pt)
|
2011-06-03 |
2020-04-28 |
3M Innovative Properties Co |
compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
|
EP2717909B1
(en)
|
2011-06-04 |
2017-12-06 |
Rochester General Hospital Research Institute |
Compositions and methods related to p6 of haemophilus influenzae
|
BR112013031564B1
(pt)
|
2011-06-07 |
2021-11-03 |
Ibio, Inc |
Métodos para geração e expressão de um polipeptídio e sistema de expressão
|
KR102033185B1
(ko)
|
2011-06-17 |
2019-10-16 |
유니버시티 오브 테네시 리서치 파운데이션 |
그룹 a 스트렙토콕쿠스 다가 백신
|
CN103732749B
(zh)
|
2011-06-20 |
2017-03-29 |
高等教育联邦系统-匹兹堡大学 |
计算优化的宽反应性的h1n1流感抗原
|
WO2012177595A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
WO2013007703A1
(en)
*
|
2011-07-08 |
2013-01-17 |
Universität Zürich |
CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS
|
BR112014001244A2
(pt)
|
2011-07-19 |
2017-02-21 |
Wave Life Sciences Pte Ltd |
métodos para a síntese de ácidos nucléicos funcionalizados
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
CA2843274A1
(en)
|
2011-07-29 |
2013-02-07 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
|
GB201114919D0
(en)
|
2011-08-30 |
2011-10-12 |
Glaxosmithkline Biolog Sa |
Method
|
WO2013039792A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunogens based on an hiv-1 gp120 v1v2 epitope
|
CA2848611A1
(en)
|
2011-09-16 |
2013-03-21 |
Ucb Pharma S.A. |
Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
|
PT2572725E
(pt)
|
2011-09-21 |
2015-10-20 |
Ruprecht Karls Universität Heidelberg |
Péptidos frameshift específicos de ims para a prevenção e tratamento do cancro¿
|
US20140234360A1
(en)
|
2011-09-30 |
2014-08-21 |
The United States of America, as represented by the Secretary, Dept.of Health and Human Services |
Influenza vaccine
|
AU2012318694B2
(en)
|
2011-10-04 |
2016-12-22 |
Janus Biotherapeutics, Inc. |
Novel imidazole quinoline-based immune system modulators
|
WO2013059493A1
(en)
|
2011-10-20 |
2013-04-25 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
EP2596806A1
(en)
|
2011-11-25 |
2013-05-29 |
Index Pharmaceuticals AB |
Method for prevention of colectomy
|
CN104144693A
(zh)
|
2012-01-16 |
2014-11-12 |
E·麦肯纳 |
用于治疗肝脏疾病和障碍的组合物和方法
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
CN110339160A
(zh)
|
2012-02-07 |
2019-10-18 |
传染性疾病研究院 |
包含tlr4激动剂的改进佐剂制剂及其使用方法
|
MX2014009148A
(es)
|
2012-02-07 |
2014-09-22 |
Univ Pittsburgh |
Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h3n2, h2n2 y b.
|
MX359071B
(es)
|
2012-02-13 |
2018-09-13 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Antígenos ampliamente reactivos computacionalmente optimizados para influenza h5n1 humana y aviar.
|
US9421250B2
(en)
|
2012-03-23 |
2016-08-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
ES2702278T3
(es)
|
2012-04-01 |
2019-02-28 |
Technion Res & Dev Foundation |
Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
|
WO2013158673A1
(en)
|
2012-04-16 |
2013-10-24 |
President And Fellows Of Harvard College |
Mesoporous silica compositions for modulating immune responses
|
US9597385B2
(en)
|
2012-04-23 |
2017-03-21 |
Allertein Therapeutics, Llc |
Nanoparticles for treatment of allergy
|
SG10201603896RA
(en)
|
2012-05-04 |
2016-07-28 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
MX350274B
(es)
|
2012-05-16 |
2017-08-31 |
Immune Design Corp |
Vacunas para hsv-2.
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
CN104470537B
(zh)
|
2012-05-23 |
2017-04-26 |
美国政府(由卫生和人类服务部的部长所代表) |
表达鼠疫耶尔森氏菌F1‑V融合蛋白的伤寒沙门氏菌Ty21a及其用途
|
US9427476B2
(en)
|
2012-05-24 |
2016-08-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Multivalent meningococcal conjugates and methods for preparing conjugates
|
US9687542B2
(en)
|
2012-06-19 |
2017-06-27 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Rift valley fever virus replicon particles and use thereof
|
EP2873674B1
(en)
|
2012-07-13 |
2020-05-06 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant
|
BR112015000784A8
(pt)
|
2012-07-13 |
2018-04-03 |
Wave Life Sciences Japan |
Grupo auxiliar assimétrico
|
EP2872147B1
(en)
|
2012-07-13 |
2022-12-21 |
Wave Life Sciences Ltd. |
Method for making chiral oligonucleotides
|
JP2015525784A
(ja)
|
2012-08-03 |
2015-09-07 |
インフェクティアス ディジーズ リサーチ インスティチュート |
活動性結核菌感染を治療するための組成物及び方法
|
CA2879939A1
(en)
|
2012-08-06 |
2014-02-13 |
Glaxosmithkline Biologicals S.A. |
Novel method
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
WO2014037124A1
(en)
|
2012-09-04 |
2014-03-13 |
Bavarian Nordic A/S |
Methods and compositions for enhancing vaccine immune responses
|
US20150224181A1
(en)
|
2012-09-14 |
2015-08-13 |
The United States Of America As Represented By The Secretary Department Of Health And Human Se |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
WO2014043189A1
(en)
|
2012-09-14 |
2014-03-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Conditionally replication deficient herpes viruses and use thereof in vaccines
|
WO2014043535A1
(en)
|
2012-09-14 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions for the treatment of cancer
|
JP2015535829A
(ja)
|
2012-09-21 |
2015-12-17 |
マッケーナ、エリザベス |
天然に存在するCpGオリゴヌクレオチド組成物およびその治療的適用
|
ES2854754T3
(es)
|
2012-10-24 |
2021-09-22 |
Platelet Targeted Therapeutics Llc |
Tratamiento dirigido a plaquetas
|
RU2644677C2
(ru)
|
2012-12-13 |
2018-02-13 |
Рупрехт-Карлс-Университэт Гейдельберг |
Мсн-специфичные пептиды со смещенной рамкой считывания (псрс) для предотвращения и лечения рака
|
LT2941233T
(lt)
|
2013-01-07 |
2020-10-26 |
The Trustees Of The University Of Pennsylvania |
Odos t-ląstelių limfomos gydymo kompozicija ir būdas
|
CA2936092A1
(en)
|
2013-01-23 |
2014-07-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Stabilized hepatitis b core polypeptide
|
AR095425A1
(es)
|
2013-03-15 |
2015-10-14 |
Glaxosmithkline Biologicals Sa |
Vacuna, uso y procedimiento para prevenir una infección por picornavirus
|
BR112015024860B1
(pt)
|
2013-03-28 |
2023-11-07 |
Access To Advanced Health Institute |
Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
|
EP2981285B1
(en)
|
2013-04-03 |
2020-06-03 |
N-Fold Llc |
Novel nanoparticle compositions
|
BR112015025709A2
(pt)
|
2013-04-18 |
2017-07-18 |
Immune Design Corp |
monoterapia com gla para uso em tratamento de câncer
|
US20160083698A1
(en)
|
2013-04-19 |
2016-03-24 |
The Regents Of The University Of California |
Lone star virus
|
CA2909586C
(en)
|
2013-05-15 |
2021-08-31 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
WO2014201245A1
(en)
|
2013-06-12 |
2014-12-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
|
JP6697384B2
(ja)
|
2013-07-25 |
2020-05-20 |
イグジキュア, インコーポレーテッドExicure, Inc. |
予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物
|
EP3632458A1
(en)
|
2013-07-26 |
2020-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
EP3492097A1
(en)
|
2013-08-05 |
2019-06-05 |
GlaxoSmithKline Biologicals S.A. |
Combination immunogenic compositions
|
RU2723328C2
(ru)
|
2013-08-21 |
2020-06-09 |
Куревак Аг |
Вакцина против респираторно-синцитиального вируса (рсв)
|
EP3049114B1
(en)
|
2013-09-27 |
2021-11-10 |
Massachusetts Institute of Technology |
Carrier-free biologically-active protein nanostructures
|
US10010606B2
(en)
|
2013-09-30 |
2018-07-03 |
Los Alamos National Security, Llc |
Mosaic conserved region HIV immunogenic polypeptides
|
EP3052127A1
(en)
|
2013-10-04 |
2016-08-10 |
PIN Pharma, Inc. |
Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
|
HUE043042T2
(hu)
|
2013-11-01 |
2019-07-29 |
Pfizer |
Vektorok prosztatához kapcsolódó antigének expressziójára
|
US10208102B2
(en)
|
2013-11-01 |
2019-02-19 |
University Of Oslo |
Albumin variants and uses thereof
|
WO2015070207A2
(en)
|
2013-11-11 |
2015-05-14 |
The Government Of The United States, As Represented By The Secretary Of The Army |
Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
|
CA2929126C
(en)
|
2013-11-13 |
2020-01-07 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
WO2015071763A2
(en)
|
2013-11-15 |
2015-05-21 |
Oslo Universitetssykehus Hf |
Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
CA2931112A1
(en)
|
2013-11-20 |
2015-05-28 |
La Jolla Institute For Allergy And Immunology |
Pan pollen immunogens and methods and uses for immune response modulation
|
WO2015077442A2
(en)
|
2013-11-20 |
2015-05-28 |
La Jolla Institute For Allergy And Immunology |
Grass pollen immunogens and methods and uses for immune response modulation
|
AU2014356546A1
(en)
|
2013-11-28 |
2016-06-02 |
Bavarian Nordic A/S |
Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
|
EP3079716B1
(en)
|
2013-12-13 |
2019-05-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Multi-epitope tarp peptide vaccine and uses thereof
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
CN106163551A
(zh)
|
2013-12-31 |
2016-11-23 |
传染性疾病研究院 |
单瓶疫苗制剂
|
WO2015108047A1
(ja)
*
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
JPWO2015108046A1
(ja)
*
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
JPWO2015108048A1
(ja)
*
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
KR20230152178A
(ko)
|
2014-01-16 |
2023-11-02 |
웨이브 라이프 사이언시스 리미티드 |
키랄 디자인
|
US20160324949A1
(en)
|
2014-01-21 |
2016-11-10 |
Pfizer Inc. |
Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
|
WO2015112485A1
(en)
|
2014-01-21 |
2015-07-30 |
Immune Design Corp. |
Compositions for use in the treatment of allergic conditions
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
PT3096783T
(pt)
|
2014-01-21 |
2021-08-16 |
Pfizer |
Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos
|
CN114887048A
(zh)
|
2014-01-21 |
2022-08-12 |
辉瑞公司 |
包含缀合荚膜糖抗原的免疫原性组合物及其用途
|
EP3104877B1
(en)
|
2014-02-11 |
2020-01-22 |
The USA, as represented by The Secretary, Department of Health and Human Services |
Pcsk9 vaccine and methods of using the same
|
TW201620927A
(zh)
|
2014-02-24 |
2016-06-16 |
葛蘭素史密斯克藍生物品公司 |
Uspa2蛋白質構築體及其用途
|
WO2015131053A1
(en)
|
2014-02-28 |
2015-09-03 |
Alk-Abelló A/S |
Polypeptides derived from phl p and methods and uses thereof for immune response modulation
|
US10369216B2
(en)
|
2014-04-01 |
2019-08-06 |
Curevac Ag |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
US10111948B2
(en)
|
2014-04-25 |
2018-10-30 |
Tria Bioscience Corp. |
Synthetic hapten carrier compositions and methods
|
EP3137105A4
(en)
|
2014-04-30 |
2017-12-27 |
President and Fellows of Harvard College |
Combination vaccine devices and methods of killing cancer cells
|
CA2986096A1
(en)
|
2014-05-30 |
2015-12-03 |
Sanofi Pasteur Inc. |
Expression and conformational analysis of engineered influenza hemagglutinin
|
AU2015269412B2
(en)
|
2014-06-04 |
2020-03-12 |
Exicure Operating Company |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
EP2952893A1
(en)
|
2014-06-04 |
2015-12-09 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Method for detecting antibody-secreting B cells specific for HLA
|
JP6664338B2
(ja)
|
2014-06-13 |
2020-03-13 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組合せ物
|
CA2955015A1
(en)
|
2014-07-15 |
2016-01-21 |
Immune Design Corp. |
Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
|
US10759836B2
(en)
|
2014-07-18 |
2020-09-01 |
University Of Washington |
Cancer vaccine compositions and methods of use thereof
|
AR101256A1
(es)
|
2014-07-21 |
2016-12-07 |
Sanofi Pasteur |
Composición vacunal que comprende ipv y ciclodextrinas
|
EP3183251A4
(en)
|
2014-08-22 |
2017-12-27 |
Janus Biotherapeutics, Inc. |
Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
|
AU2015328242A1
(en)
|
2014-10-06 |
2017-04-27 |
Exicure, Inc. |
Anti-TNF compounds
|
ES2924988T3
(es)
|
2014-10-10 |
2022-10-13 |
Univ Michigan Regents |
Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
AR102548A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
|
WO2016081911A2
(en)
|
2014-11-21 |
2016-05-26 |
Northwestern University |
The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
|
US20170281744A1
(en)
|
2014-12-10 |
2017-10-05 |
Glaxosmithkline Biologicals Sa |
Method of treatment
|
CN113563468A
(zh)
|
2014-12-19 |
2021-10-29 |
雷根尼桑斯公司 |
结合人c6的抗体及其用途
|
SI3240801T1
(sl)
|
2014-12-31 |
2021-04-30 |
Checkmate Pharmaceuticals, Inc. |
Kombinirana imunoterapija tumorja
|
CN113456812A
(zh)
|
2015-01-09 |
2021-10-01 |
埃图比克斯公司 |
用于联合免疫治疗的方法和组合物
|
BR112017013891B1
(pt)
|
2015-01-15 |
2024-01-30 |
Pfizer Inc |
Composições imunogênicas para uso em vacinas pneumocócicas
|
WO2016123573A1
(en)
|
2015-01-30 |
2016-08-04 |
President And Fellows Of Harvard College |
Peritumoral and intratumoral materials for cancer therapy
|
US20180036334A1
(en)
|
2015-02-13 |
2018-02-08 |
Icahn School Of Medicine At Mount Sinai |
Rna containing compositions and methods of their use
|
CA2977493C
(en)
|
2015-03-03 |
2023-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Display platform from bacterial spore coat proteins
|
CN107530416A
(zh)
|
2015-03-05 |
2018-01-02 |
西北大学 |
非神经侵染的病毒及其用途
|
EP3268037B1
(en)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
US20180071380A1
(en)
|
2015-03-20 |
2018-03-15 |
The Regents Of The University Of Michigan |
Immunogenic compositions for use in vaccination against bordetella
|
CN116603058A
(zh)
|
2015-03-26 |
2023-08-18 |
Gpn疫苗有限公司 |
链球菌疫苗
|
JP7094533B2
(ja)
|
2015-04-10 |
2022-07-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
免疫細胞捕捉デバイスおよびその製造および使用方法
|
EP3286213B1
(en)
|
2015-04-20 |
2021-08-04 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
WO2016180852A1
(en)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing antigen-specific t cells from an umbilical cord blood sample
|
EA201792501A1
(ru)
|
2015-05-13 |
2018-10-31 |
Эйдженус Инк. |
Вакцины для лечения и профилактики рака
|
BR112017025316A2
(pt)
|
2015-05-26 |
2018-07-31 |
Ohio State Innovation Foundation |
estratégia de vacina baseada em nanopartículas contra o vírus da gripe suína
|
CA2987939A1
(en)
|
2015-06-02 |
2016-12-08 |
Sanofi Pasteur Inc. |
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
DK3307878T3
(da)
|
2015-06-10 |
2021-10-11 |
Us Health |
Fremgangsmåder til fremstilling og oprensning af nukleinsyreholdige sammensætninger
|
MX2017017141A
(es)
*
|
2015-06-26 |
2018-03-09 |
Bayer Animal Health Gmbh |
Metodos de modulacion de moleculas de vigilancia de adn citosolicas.
|
WO2017013548A1
(en)
|
2015-07-21 |
2017-01-26 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
AU2016305087B2
(en)
|
2015-08-12 |
2022-01-20 |
Massachusetts Institute Of Technology |
Cell surface coupling of nanoparticles
|
KR20180053318A
(ko)
|
2015-09-17 |
2018-05-21 |
제이알엑스 바이오테크놀로지, 인코포레이티드 |
피부 수화 또는 보습을 향상시키기 위한 접근법
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
CN108431214B
(zh)
|
2015-10-05 |
2022-03-01 |
美国政府(由卫生和人类服务部的部长所代表) |
人轮状病毒g9p[6]毒株和作为疫苗的用途
|
GB201518668D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Immunogenic Comosition
|
EP3368067B1
(en)
|
2015-10-30 |
2021-05-19 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Compositions and methods for the treatment of her2-expressing solid tumors
|
CA3005524C
(en)
|
2015-11-20 |
2023-10-10 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
WO2017120504A1
(en)
|
2016-01-08 |
2017-07-13 |
Durfee Paul N |
Osteotropic nanoparticles for prevention or treatment of bone metastases
|
DK3407910T3
(da)
|
2016-01-29 |
2022-07-18 |
Bavarian Nordic As |
Rekombinant modificeret vaccinia virus ankara (mva)-vaccine mod hesteencephalitisvirus
|
US11752238B2
(en)
|
2016-02-06 |
2023-09-12 |
President And Fellows Of Harvard College |
Recapitulating the hematopoietic niche to reconstitute immunity
|
CN109562154A
(zh)
|
2016-03-10 |
2019-04-02 |
爱普瑞希斯有限公司 |
带有修饰hsp70域的抗原结合融合蛋白
|
KR20180127320A
(ko)
|
2016-03-14 |
2018-11-28 |
유니버시티에트 이 오슬로 |
변경된 FcRn 결합을 갖는 조작된 면역글로불린
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
WO2017173334A1
(en)
|
2016-04-01 |
2017-10-05 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
EA201892362A1
(ru)
|
2016-04-18 |
2019-04-30 |
Селлдекс Терапьютикс, Инк. |
Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
|
WO2017189448A1
(en)
|
2016-04-25 |
2017-11-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bivalent immunogenic conjugate for malaria and typhoid
|
KR102392974B1
(ko)
|
2016-05-16 |
2022-05-02 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
Tlr 작용제를 함유하는 제제 및 사용 방법
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
EP3458088A2
(en)
|
2016-05-21 |
2019-03-27 |
Infectious Disease Research Institute |
Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
|
CA3025648A1
(en)
|
2016-05-27 |
2017-11-30 |
Etubics Corporation |
Neoepitope vaccine compositions and methods of use thereof
|
MX2021010105A
(es)
|
2016-06-01 |
2022-06-16 |
Infectious Disease Res Inst |
Particulas de nanoalumbre que contienen un agente de dimensionamiento.
|
US10844097B2
(en)
|
2016-06-02 |
2020-11-24 |
Sanofi Pasteur Inc. |
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
JP7110119B2
(ja)
|
2016-06-03 |
2022-08-01 |
サノフィ パスツール インコーポレイティッド |
改変インフルエンザヘマグルチニンポリペプチドの修飾
|
US10947277B2
(en)
|
2016-06-13 |
2021-03-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
|
WO2017218533A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
US11780924B2
(en)
|
2016-06-21 |
2023-10-10 |
University Of Oslo |
HLA binding vaccine moieties and uses thereof
|
WO2018009604A1
(en)
|
2016-07-08 |
2018-01-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric dengue/zika viruses live-attenuated zika virus vaccines
|
WO2018009603A1
(en)
|
2016-07-08 |
2018-01-11 |
The United State of America, as represented by the Secretary, Department of Health and Human Service |
Chimeric west nile/zika viruses and methods of use
|
US11555177B2
(en)
|
2016-07-13 |
2023-01-17 |
President And Fellows Of Harvard College |
Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
|
WO2018027123A1
(en)
|
2016-08-05 |
2018-02-08 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
BR112019001971A2
(pt)
|
2016-08-05 |
2019-05-07 |
Sanofi Pasteur, Inc. |
composição conjugada de polissacarídeo-proteína pneumocócica multivalente
|
US11498956B2
(en)
|
2016-08-23 |
2022-11-15 |
Glaxosmithkline Biologicals Sa |
Fusion peptides with antigens linked to short fragments of invariant chain(CD74)
|
WO2018039629A2
(en)
|
2016-08-25 |
2018-03-01 |
Northwestern University |
Micellar spherical nucleic acids from thermoresponsive, traceless templates
|
MX2019003035A
(es)
|
2016-09-16 |
2019-09-13 |
Infectious Disease Res Inst |
Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
JP7146777B2
(ja)
*
|
2016-10-07 |
2022-10-04 |
セカルナ・ファーマシューティカルズ・ゲーエムベーハー・ウント・コ・カーゲー |
Cd39の発現を阻害する免疫抑制復帰オリゴヌクレオチド
|
US10172933B2
(en)
|
2016-10-31 |
2019-01-08 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Mosaic vaccines for serotype a foot-and-mouth disease virus
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
EP3554538A2
(en)
|
2016-12-16 |
2019-10-23 |
Institute for Research in Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
HRP20220573T1
(hr)
|
2017-01-20 |
2022-06-10 |
Pfizer Inc. |
Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima
|
WO2018160865A1
(en)
|
2017-03-01 |
2018-09-07 |
Charles Jeffrey Brinker |
Active targeting of cells by monosized protocells
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
WO2018178265A1
(en)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
JP2020515587A
(ja)
|
2017-03-31 |
2020-05-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
免疫原性組成物、使用及び処置方法
|
JP7278259B2
(ja)
|
2017-04-19 |
2023-05-19 |
インスティテュート・フォー・リサーチ・イン・バイオメディシン |
ワクチン及び標的としてのプラスモジウムスポロゾイトnpdpペプチド、新規マラリアワクチン、及びそれに結合する抗体
|
US11696954B2
(en)
|
2017-04-28 |
2023-07-11 |
Exicure Operating Company |
Synthesis of spherical nucleic acids using lipophilic moieties
|
AU2018283973A1
(en)
|
2017-06-11 |
2020-01-16 |
Molecular Express, Inc. |
Methods and compositions for substance use disorder vaccine formulations and uses thereof
|
CN111315362A
(zh)
|
2017-06-15 |
2020-06-19 |
传染病研究所 |
纳米结构脂质载剂和稳定乳剂以及其用途
|
EP3655031A1
(en)
|
2017-07-21 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neisseria meningitidis immunogenic compositions
|
EP3641808A1
(en)
|
2017-08-14 |
2020-04-29 |
GlaxoSmithKline Biologicals S.A. |
Methods of boosting immune responses
|
US11123415B2
(en)
|
2017-08-16 |
2021-09-21 |
Ohio State Innovation Foundation |
Nanoparticle compositions for Salmonella vaccines
|
AU2018328209A1
(en)
|
2017-09-05 |
2020-04-23 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
EP3678698A1
(en)
|
2017-09-07 |
2020-07-15 |
University Of Oslo |
Vaccine molecules
|
WO2019048936A1
(en)
|
2017-09-07 |
2019-03-14 |
University Of Oslo |
VACCINE MOLECULES
|
EP3679139B1
(en)
|
2017-09-08 |
2022-11-02 |
MiNA Therapeutics Limited |
Stabilized hnf4a sarna compositions and methods of use
|
US20200276299A1
(en)
|
2017-09-08 |
2020-09-03 |
Infectious Disease Research Institute |
Liposomal formulations comprising saponin and methods of use
|
MY194449A
(en)
|
2017-11-03 |
2022-11-30 |
Takeda Vaccines Inc |
Zika vaccines and immunogenic compositions, and methods of using the same
|
WO2019090138A2
(en)
|
2017-11-04 |
2019-05-09 |
Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno |
Immunogenic conjugates and methods of use thereof
|
BR112020011838A2
(pt)
*
|
2017-12-15 |
2020-11-24 |
Bayer Animal Health Gmbh |
oligonucleotídeos imunoestimulatórios
|
US11116830B2
(en)
|
2017-12-18 |
2021-09-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacterial polysaccharide-conjugated carrier proteins and use thereof
|
EP3727447A1
(en)
|
2017-12-19 |
2020-10-28 |
Massachusetts Institute of Technology |
Antigen-adjuvant coupling reagents and methods of use
|
GB201721582D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
S aureus antigens and immunogenic compositions
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
US11369675B2
(en)
|
2018-01-22 |
2022-06-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly protective inactivated influenza virus vaccine
|
EP3743102A1
(en)
|
2018-01-26 |
2020-12-02 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
EP3527223A1
(en)
|
2018-02-16 |
2019-08-21 |
2A Pharma AB |
Mutated parvovirus structural protein
|
WO2019158636A1
(en)
|
2018-02-16 |
2019-08-22 |
2A Pharma Ab |
Parvovirus structural protein for the treatment of autoimmune diseases
|
SG11202007518RA
(en)
|
2018-02-28 |
2020-09-29 |
Pfizer |
Il-15 variants and uses thereof
|
WO2019173438A1
(en)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions and methods for reducing serum triglycerides
|
EP3774884B1
(en)
|
2018-03-28 |
2023-12-06 |
Sanofi Pasteur Inc. |
Methods of generating broadly protective vaccine compositions comprising hemagglutinin
|
WO2019195276A1
(en)
|
2018-04-03 |
2019-10-10 |
Sanofi |
Antigenic ospa polypeptides
|
WO2019195291A1
(en)
|
2018-04-03 |
2019-10-10 |
Sanofi |
Antigenic respiratory syncytial virus polypeptides
|
EP3773703A1
(en)
|
2018-04-03 |
2021-02-17 |
Sanofi |
Antigenic influenza-ferritin polypeptides
|
EP3773698A1
(en)
|
2018-04-03 |
2021-02-17 |
Sanofi |
Ferritin proteins
|
WO2019195314A2
(en)
|
2018-04-03 |
2019-10-10 |
Sanofi |
Antigenic epstein barr virus polypeptides
|
SG11202010011RA
(en)
|
2018-04-17 |
2020-11-27 |
Celldex Therapeutics Inc |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
WO2019224716A2
(en)
|
2018-05-23 |
2019-11-28 |
Pfizer Inc. |
Antibodies specific for gucy2c and uses thereof
|
KR102602329B1
(ko)
|
2018-05-23 |
2023-11-16 |
화이자 인코포레이티드 |
Cd3에 특이적인 항체 및 이의 용도
|
US11702674B2
(en)
|
2018-06-12 |
2023-07-18 |
Glaxosmithkline Biologicals Sa |
Simian adenovirus vectors comprising the ChAd-157 fiber protein
|
BR112021000529A2
(pt)
|
2018-07-19 |
2021-04-06 |
Glaxosmithkline Biologicals S.A. |
Processos para preparar polissacarídeos secos
|
BR112021000965A2
(pt)
|
2018-08-07 |
2021-04-27 |
Glaxosmithkline Biologicals S.A. |
processos e vacinas
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
EP3851120A4
(en)
|
2018-09-11 |
2022-04-27 |
Shanghai Public Health Clinical Center |
IMMUNOGEN FOR BROAD-SPECTRUM INFLUENZA VACCINE, AND APPLICATION THEREOF
|
CA3120324A1
(en)
|
2018-12-04 |
2020-06-11 |
The Rockefeller University |
Hiv vaccine immunogens
|
EP3890775A1
(en)
|
2018-12-06 |
2021-10-13 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
US20220023413A1
(en)
|
2018-12-12 |
2022-01-27 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
|
EP3894431A2
(en)
|
2018-12-12 |
2021-10-20 |
GlaxoSmithKline Biologicals SA |
Modified carrier proteins for o-linked glycosylation
|
WO2020121159A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
EP3894429B1
(en)
|
2018-12-14 |
2024-02-21 |
University of Georgia Research Foundation, Inc. |
Crimean-congo hemorrhagic fever virus replicon particles and use thereof
|
EP3897846A1
(en)
|
2018-12-21 |
2021-10-27 |
GlaxoSmithKline Biologicals SA |
Methods of inducing an immune response
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
EP3946446A1
(en)
|
2019-04-02 |
2022-02-09 |
Sanofi |
Antigenic multimeric respiratory syncytial virus polypeptides
|
JP2022528158A
(ja)
|
2019-04-10 |
2022-06-08 |
ファイザー・インク |
コンジュゲート化莢膜糖抗原を含む免疫原性組成物、それを含むキットおよびその使用
|
EP3956666A1
(en)
|
2019-04-18 |
2022-02-23 |
GlaxoSmithKline Biologicals S.A. |
Antigen binding proteins and assays
|
JP2022533318A
(ja)
|
2019-05-20 |
2022-07-22 |
ヴァルネヴァ エスイー |
気道感染の治療または予防のためのサブユニットワクチン
|
US20220249646A1
(en)
|
2019-05-25 |
2022-08-11 |
Infectious Disease Research Institute |
Composition and method for spray drying an adjuvant vaccine emulsion
|
WO2020240268A1
(en)
|
2019-05-31 |
2020-12-03 |
Universidad De Chile |
An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec)
|
EP3770269A1
(en)
|
2019-07-23 |
2021-01-27 |
GlaxoSmithKline Biologicals S.A. |
Quantification of bioconjugate glycosylation
|
BR112021026565A2
(pt)
|
2019-08-05 |
2022-05-03 |
Glaxosmithkline Biologicals Sa |
Composição imunogênica
|
EP4021894A1
(en)
|
2019-08-30 |
2022-07-06 |
University of Rochester |
Septin inhibitors for treatment of cancers
|
EP3799884A1
(en)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
JP2021087420A
(ja)
|
2019-11-01 |
2021-06-10 |
ファイザー・インク |
Escherichia coli組成物およびその方法
|
WO2021097347A1
(en)
|
2019-11-15 |
2021-05-20 |
Infectious Disease Research Institute |
Rig-i agonist and adjuvant formulation for tumor treatment
|
US20220387614A1
(en)
|
2019-11-22 |
2022-12-08 |
Glaxosmithkline Biologicals Sa |
Dosage and administration of a bacterial saccharide glycoconjugate vaccine
|
BR112022010228A2
(pt)
|
2019-12-17 |
2022-09-06 |
Us Health |
Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas
|
AU2020410410A1
(en)
|
2019-12-17 |
2022-06-09 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
AU2021223184A1
(en)
|
2020-02-23 |
2022-08-18 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2021173907A1
(en)
|
2020-02-28 |
2021-09-02 |
Sanofi Pasteur, Inc. |
High dose influenza vaccine for pediatric subjects
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
CN116323668A
(zh)
|
2020-07-17 |
2023-06-23 |
辉瑞公司 |
治疗性抗体及其用途
|
JP7407081B2
(ja)
|
2020-07-20 |
2023-12-28 |
三菱重工機械システム株式会社 |
印刷機および印刷機の後片付け方法
|
WO2022051022A1
(en)
|
2020-09-04 |
2022-03-10 |
Infectious Disease Research Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
JP2023542528A
(ja)
|
2020-09-24 |
2023-10-10 |
フレッド ハッチンソン キャンサー センター |
Sox2抗原を標的とする免疫療法
|
WO2022066973A1
(en)
|
2020-09-24 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting pbk or oip5 antigens
|
WO2022074061A1
(en)
|
2020-10-07 |
2022-04-14 |
Valneva Sweden Ab |
Cholera vaccine formulation
|
WO2022083768A1
(zh)
|
2020-10-23 |
2022-04-28 |
江苏省疾病预防控制中心(江苏省公共卫生研究院) |
免疫原性组合物及其应用
|
CA3199610A1
(en)
|
2020-10-27 |
2022-05-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
IL302413A
(en)
|
2020-11-04 |
2023-06-01 |
Pfizer |
Immunogenic preparations for use in pneumococcal vaccines
|
US20230405137A1
(en)
|
2020-11-10 |
2023-12-21 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
CN117120087A
(zh)
|
2020-12-23 |
2023-11-24 |
高级健康研究所 |
茄尼醇疫苗助剂及其制备方法
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
JP2024510717A
(ja)
|
2021-02-22 |
2024-03-11 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物、使用及び方法
|
WO2022207793A1
(en)
|
2021-03-31 |
2022-10-06 |
Vib Vzw |
Vaccine compositions for trypanosomatids
|
WO2022214685A2
(en)
|
2021-04-09 |
2022-10-13 |
Valneva Se |
Human metapneumovirus combination vaccine
|
JP2024515560A
(ja)
|
2021-04-09 |
2024-04-10 |
セルデックス セラピューティクス インコーポレイテッド |
Ilt4に対する抗体、二重特異性の抗ilt4/pd-l1抗体、およびそれらの使用方法
|
KR20240004764A
(ko)
|
2021-04-30 |
2024-01-11 |
칼리버 임뮤노쎄라퓨틱스, 인크. |
변형된 mhc 발현을 위한 종양용해성 바이러스
|
CA3221074A1
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
CA3221075A1
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
AU2022311955A1
(en)
|
2021-07-16 |
2024-01-18 |
The Board Of Trustees Of The University Of Illinois |
Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
|
WO2023018817A1
(en)
|
2021-08-11 |
2023-02-16 |
Sanofi Pasteur Inc. |
Truncated influenza neuraminidase and methods of using the same
|
TW202333778A
(zh)
|
2021-10-08 |
2023-09-01 |
美商賽諾菲巴斯德公司 |
多價流感疫苗
|
AR127585A1
(es)
|
2021-11-05 |
2024-02-07 |
Sanofi Sa |
Vacuna de arn de virus sincicial respiratorio
|
WO2023081798A1
(en)
|
2021-11-05 |
2023-05-11 |
Sanofi Pasteur Inc. |
Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same
|
WO2023079113A1
(en)
|
2021-11-05 |
2023-05-11 |
Sanofi |
Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
WO2023083964A1
(en)
|
2021-11-11 |
2023-05-19 |
2A Pharma Ab |
Parvovirus structural protein against beta- and gamma-hpv
|
WO2023102373A1
(en)
|
2021-11-30 |
2023-06-08 |
Sanofi Pasteur Inc. |
Human metapneumovirus vaccines
|
WO2023102388A1
(en)
|
2021-11-30 |
2023-06-08 |
Sanofi Pasteur Inc. |
Human metapneumovirus viral vector-based vaccines
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
WO2023111262A1
(en)
|
2021-12-17 |
2023-06-22 |
Sanofi |
Lyme disease rna vaccine
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023144206A1
(en)
|
2022-01-27 |
2023-08-03 |
Sanofi Pasteur |
Modified vero cells and methods of using the same for virus production
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023177577A1
(en)
|
2022-03-14 |
2023-09-21 |
Sanofi Pasteur Inc. |
Machine-learning techniques in protein design for vaccine generation
|
WO2023214082A2
(en)
|
2022-05-06 |
2023-11-09 |
Sanofi |
Signal sequences for nucleic acid vaccines
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2023232901A1
(en)
|
2022-06-01 |
2023-12-07 |
Valneva Austria Gmbh |
Clostridium difficile vaccine
|
WO2024003239A1
(en)
|
2022-06-29 |
2024-01-04 |
Bavarian Nordic A/S |
RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
|
WO2024052882A1
(en)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|